Crystalline hydrate of JAK inhibitor compounds
A crystalline hydrate form of a JAK inhibitor compound is developed, addressing the unpredictability of crystalline formation and ensuring thermal stability and targeted delivery for treating respiratory diseases and lung transplant rejection.
Patent Information
- Application Number
- KR1020227034088
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-03-02
- Filing Date
- 2021-03-01
- Publication Date
- 2026-11-11
- Estimated Expiration
- 2041-03-01
AI Technical Summary
There is a need for a thermally stable crystalline form of a JAK inhibitor compound to facilitate its use as a therapeutic agent for treating respiratory diseases and lung transplant rejection, as the formation of a crystalline form of organic compounds is unpredictable and their physical properties are not reliably predictable for pharmaceutical use.
The development of a crystalline hydrate form of the JAK inhibitor compound, characterized by specific X-ray diffraction peaks and thermal stability, which can be prepared through a controlled crystallization process.
The crystalline hydrate form exhibits excellent thermal stability and moisture sorption properties, enabling effective delivery of the JAK inhibitor to the lungs while minimizing systemic absorption, thus providing therapeutic benefits for respiratory diseases and lung transplant rejection.
Smart Images

Figure 112022103081719-PCT00033_ABST
Abstract
Description
Technology Field
[0001] The present invention provides a crystalline hydrate of a JAK inhibitor compound useful for treating respiratory and other diseases. The present invention also provides a pharmaceutical composition comprising said crystalline form, for example, a method of using said crystalline form to treat respiratory diseases, and a process useful for preparing said crystalline form. Background Technology
[0002] Cytokines are intercellular signaling molecules that include chemokines, interferons, interleukins, lymphokines, and tumor necrosis factor. Cytokines are not only important for normal cell proliferation and immune regulation but also induce immune-mediated diseases and contribute to malignant cell proliferation. Increased levels of many cytokines are associated with the pathology of many diseases or conditions, specifically diseases characterized by inflammation. Many disease-related cytokines act through signaling pathways dependent on the Janus family of tyrosine kinases (JAK), which transmit signals through the Signal Transducer and Activator of Transcription (STAT) family of transcription factors.
[0003] The above JAK family includes four members: JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). Binding of cytokines to JAK-dependent cytokine receptors induces receptor dimerization, which leads to the phosphorylation of tyrosine residues in JAK kinases and affects JAK activation. Phosphorylated JAKs bind to and phosphorylate various STAT proteins that are dimerized and internalized within the cell nucleus and directly regulate gene transcription, thereby inducing downstream effects associated with inflammatory diseases among other effects. The above JAKs typically associate with cytokine receptors as homodimers or heterodimers. Specific cytokines are associated with specific JAK pairings. Each of the four members of the JAK family is involved in the signaling of at least one of the cytokines associated with inflammation.
[0004] Asthma is a chronic airway disease for which there is no prevention or cure. The disease is characterized by inflammation, fibrosis, hyperresponsiveness, and remodeling of the airways, all of which contribute to restricting airflow. Approximately 300 million people worldwide suffer from asthma, and the number of asthma patients is estimated to increase to over 100 million by 2025. While most patients can control their asthma symptoms using inhaled corticosteroids, which can be combined with leukotriene modifiers and / or long-acting beta-agonists, there remains a group of patients with severe asthma whose condition is not controlled by conventional therapy. Cytokines involved in asthmatic inflammation that signal via the JAK-STAT pathway include IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-11, IL-13, IL-23, IL-31, IL-27, thymic stromal lymphopoietin (TSLP), interferon-γ (IFNγ), and granulocyte-macrophage colony-stimulating factor (GM-CSF). Airway inflammation is a characteristic of respiratory diseases other than asthma. Chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), pneumonia, interstitial lung disease (including idiopathic pulmonary fibrosis), acute lung injury, acute respiratory distress syndrome, bronchitis, emphysema, and bronchiolitis obliterans are also airway diseases in which the pathophysiology is believed to be related to JAK-signaling cytokines.
[0005] JAK signaling cytokines also play a major role in the activation of T cells, a subtype of immune cells important for many immune processes. Pathological T cell activation is important in the pathogenesis of numerous respiratory diseases. Autoreactive T cells play a role in bronchiolitis obliterans organizing pneumonia (also known as COS). Similar to COS, the pathogenesis of lung transplant rejection is associated with aberrant T cell activation of recipient T cells by the transplanted donor lung. Lung transplant rejection can initially manifest as primary progenitor disease (PGD), organizing pneumonia (OP), acute rejection (AR), or lymphocytic bronchiolitis (LB), or it can develop into chronic lung allograft disease (CLAD) several years after transplantation. CLAD was previously known as bronchiolitis obliterans (BO), but it is now considered a syndrome with distinct pathological manifestations, including BO, restrictive CLAD (rCLAD or RAS), and neutrophilic allograft dysfunction. Chronic lung allograft dysfunction (CLAD) is a major challenge in the long-term management of lung transplant recipients because it causes the transplanted lung to gradually lose function (Gauthier et al., Curr Transplant Rep ., 2016 , 3(3), 185-191). Since CLAD does not respond well to treatment, effective compounds capable of preventing or treating this pathological condition are still needed. Several JAK-dependent cytokines, such as IFNγ and IL-5, are upregulated in CLAD and lung transplant rejection (Berastegui et al, Clin Transplant. 2017, 31, e12898). Furthermore, high lung levels of CXCR3 chemokines, such as CXCL9 and CXCL10, which are downstream of JAK-dependent IFN signaling, are associated with poor prognosis in lung transplant patients (Shino et al, PLOS One , 2017 , 12 (7), e0180281). Systemic JAK inhibition has been found to be effective in kidney transplant rejection (Vicenti et al., American Journal of Transplantation , 2012 , 12, 2446-56). Therefore, JAK inhibitors may be effective in preventing or delaying lung transplant rejection and CLAD. Similar T-cell activation events described as the basis for lung transplant rejection are also considered a major driver of lung graft-versus-host disease (GVHD) that can occur after hematopoietic stem cell transplantation. Similar to CLAD, pulmonary GVHD is a chronic, progressive condition with an extremely poor prognosis, and there are currently no approved treatments. In a retrospective, multicenter study of 95 steroid-refractory acute or chronic GVHD patients receiving the systemic JAK inhibitor ruxolitinib as salvage therapy, complete or partial remission was achieved with ruxolitinib in the majority of patients, including those with pulmonary GVHD (Zeiser et al, Leukemia 2015, 29, 10, 2062-68).
[0006] Commonly assigned U.S. Application Serial No. 16 / 559,077, filed on September 3, 2019, discloses several dimethylaminoazetidine amide compounds useful as JAK inhibitors. In particular, ( S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H-Imidazō[4,5-c]pyridin-6-yl)methanone (compound 1 ):
[0007]
[0008] It is disclosed specifically as a potent non-systemic pan-JAK inhibitor suitable for treating, preventing, and / or delaying inflammatory respiratory diseases, including asthma and lung transplant rejection.
[0009] To effectively use the above-mentioned compound as a therapeutic agent, it may be desirable for it to have a crystalline solid-state form. For example, it may be highly desirable to have a physical form that is thermally stable at significantly high temperatures to facilitate the processing and storage of the material. Crystalline solids are generally more desirable than amorphous forms for enhancing the purity and stability of the product. However, the formation of a crystalline form of an organic compound is very difficult to predict. There is no reliable method to predict whether the form of an organic compound will become crystalline. Furthermore, there is no method to predict whether the crystalline form will possess physical properties desirable for use as a pharmaceutical active agent. The problem to be solved
[0010] Therefore, compounds 1 There is a need for the determinant of. means of solving the problem
[0011] In this institution, the chemical formula 1 Provides the crystal hydrate of the compound:
[0012]
[0013] The present invention also provides a pharmaceutical composition comprising a crystal hydrate of the present disclosure and a pharmaceutically acceptable carrier.
[0014] The present invention provides a method for preparing the crystal hydrate of the present disclosure, as well as a method for treating, preventing, delaying, and / or improving diseases that can be treated using JAK inhibitors, particularly respiratory diseases and lung transplant rejection.
[0015] In addition, the present invention provides the use of the crystalline hydrate in the manufacture of medical therapies and preparations or medicines for the treatment, prevention, delay, and / or alleviation of diseases that can be treated with JAK inhibitors, particularly respiratory diseases and lung transplant rejection. Brief explanation of the drawing
[0016] Various aspects of the present invention are illustrated with reference to the attached drawings. Fig. 1 shows a compound 1 Figure 2 shows the powder X-ray diffraction (PXRD) pattern of the crystal hydrate of the compound. 1 Figure 3 shows the differential scanning calorimetry (DSC) thermograph of the crystal hydrate of the compound. 1 Figure 4 shows the thermogravimetric analysis (TGA) plot of the crystal hydrate. The compound observed at a temperature of approximately 25 °C. 1 This shows the dynamic moisture sorption (DMS) isotherm of the crystal hydrate. Specific details for implementing the invention
[0017] definition
[0018] In describing the various aspects and embodiments of the present invention, the following terms have the following meanings unless otherwise indicated.
[0019] The term "about" means ± 5 percent of the specified value.
[0020] The term "hydrate" means a complex or aggregate, typically in crystalline form, formed by water molecules and molecules of the compound of the present invention, and the ratio of water molecules to compound molecules may be 1:1, less than 1:1, or greater than 1:1.
[0021] Where the term “substantially” refers, for example, to an X-ray diffraction pattern, DSC trace, or TGA trace, it includes a pattern or trace that, while not necessarily identical to that described herein, falls within the range of experimental error or deviation as considered by a person skilled in the art.
[0022] The term "therapeutically effective amount" refers to a sufficient amount that has a therapeutic effect when administered to a patient requiring treatment.
[0023] The terms "treating" or "treatment" mean improving or suppressing a medical condition, disease, or disorder (e.g., respiratory disease) being treated in a patient (particularly a human); or alleviating the symptoms of said medical condition, disease, or disorder.
[0024] It should be noted that the singular forms "a," "an," "one," and "the" used in this specification and the appended claims may include plural objects unless the context clearly indicates otherwise.
[0025] Naming conventions
[0026] compound 1 is in accordance with IUPAC rules as implemented in ChemDraw software (PerkinElmer, Inc., Cambridge, MA) S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H-Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H It was named -imidazo[4,5-c]pyridin-6-yl)methanone.
[0027] Also, compounds 1 The imidazo portion of the tetrahydroimidazopyridine moiety in the structure is an example 1 The fragment of the compound exists in tautomer form as described below:
[0028]
[0029] According to IUPAC rules, this representation may assign different numbers to the atoms of the imidazole moiety: ( S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro- 1 H -Imidazo[4,5-c]pyridine-6-yl)methanone (Structure A) vs ( S )-(3-dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro- 3 H -Imidazo[4,5-c]pyridine-6-yl)methanone (Structure B). Regardless of whether specific forms of structures are indicated or named, the present invention will also be understood to include its tautomer.
[0030] compound 1 The crystal form of
[0031] In this institution, the chemical formula 1 Provides the crystalline hydrate (crystalline form I) of the compound:
[0032]
[0033] In one embodiment, the crystal hydrate is characterized by a powder X-ray diffraction (PXRD) pattern including diffraction peaks at 2θ values of 68±0.20, 10.43±0.20, 10.94±0.20, and 13.08±0.20. The crystal hydrate may additionally be characterized by a PXRD pattern having one additional diffraction peak at a 2θ value of 8.49±0.20. The crystal hydrate may additionally be characterized by a PXRD pattern having two or more additional diffraction peaks at 2θ values selected from 11.55±0.20, 12.20±0.20, 17.06±0.20, and 26.29±0.20. The above crystal hydrate may additionally feature a PXRD pattern having additional diffraction peaks at 2θ values of 1.55±0.20, 12.20±0.20, 17.06±0.20, and 26.29±0.20.
[0034] The above crystal hydrate is 2, 3, at 2θ values selected from 5.68±0.20, 8.49±0.20, 10.43±0.20, 10.94±0.20, 11.55±0.20, 12.20±0.20, 13.08±0.20, 15.94±0.20, 16.24±0.20, 17.06±0.20, 17.60±0.20, 18.41±0.20, 18.82±0.20, 18.96±0.20, 21.90±0.20, 22.08±0.20, 22.27±0.20, 24.55±0.20, and 26.29±0.20. It can be characterized by a PXRD pattern having 4, 5, 6, 7, 8, 9, or 10 diffraction peaks.
[0035] As is well known in the field of powder X-ray diffraction, the peak position of a PXRD spectrum is relatively less sensitive to experimental details, such as sample preparation and instrument geometry, than the relative peak height. Therefore, in one embodiment, the crystal hydrate features a powder X-ray diffraction pattern in which the peak position substantially matches that shown in FIG. 1.
[0036] In another embodiment, the crystalline hydrate is characterized by its behavior when exposed to high temperatures. As shown in FIG. 2, a differential scanning calorimetry (DSC) trace recorded at a heating rate of 10°C / min exhibits a dehydration endotherm starting at approximately 55.1°C and peaking at approximately 139.4°C, and an endothermic heat flow identified as a melt transition starting at approximately 198.6°C and peaking at approximately 212.4°C. In one embodiment, the crystalline hydrate (crystalline form I) is characterized by a differential scanning calorimetry trace recorded at a heating rate of 10°C / min exhibiting a maximum endothermic heat flow at 212.4±3°C. In another embodiment, the maximum endothermic heat flow appears at 212.4±2°C. In another embodiment, the maximum endothermic heat flow is observed at 212.4±1 ℃.
[0037] In one embodiment, the crystal hydrate is a monohydrate.
[0038] The thermogravimetric analysis (TGA) trace in Fig. 3 shows a weight loss of 3.4% up to 100.0 °C. The compound dehydrates at an initiation temperature of about 27 °C. Weight loss associated with decomposition can be observed at an initiation temperature of about 248.2 °C.
[0039] The crystalline hydrate of the present invention is shown to have a reversible adsorption / desorption profile. The solid is moderately hygroscopic. The crystalline hydrate exhibited a total moisture absorption of about 5.3% when exposed to relative humidity in the range of about 0% to about 90% at room temperature, as shown in FIG. 4.
[0040] Crystalline form I is characterized by a unit cell determined by single crystal X-ray crystallography with the following values: a = 20.8736(5) Å; b = 9.15021(19) Å; c = 15.7412(3) Å; a = 90°; b = 98.4786(18)°; and g = 90°. A single crystal of crystalline form I analyzed at a temperature of 100(2) K is characterized by a monoclinic crystal system with the following values: a = 20.8736(5) Å; b = 9.15021(19) Å; c = 15.7412(3) Å; a = 90°; b = 98.4786(18)°; g = 90°; Cell volume (V) 2973.67(11) Å 3 , and space group C2.
[0041] Crystalline form I exhibited excellent stability under accelerated conditions of temperature and relative humidity as shown in Example 10.
[0042] Synthesis method
[0043] compound 1 It can be prepared from readily available starting materials using the method described in the following examples or the method described in the jointly assigned U.S. application described in the background art of this application.
[0044] Crystalline Form I can be manufactured by the following steps:
[0045] (a) a step of providing a solution by dissolving (S)-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-yl)methanone in an alcohol solvent at 55°C ±10°C;
[0046] (b) A step of cooling the solution from step (a) to 10℃ ±10℃ to produce a suspension;
[0047] (c) a step of separating the solid from the suspension of step (b) under inert gas conditions;
[0048] (d) a step of drying the solid obtained in step (c) at 60℃ ±15℃; and
[0049] (e) A step of providing a crystal hydrate by placing the solid obtained in step (d) under ambient humidity and temperature conditions.
[0050] In some embodiments, the alcohol solvent is methanol. In some embodiments, the alcohol solvent is ethanol.
[0051] In some embodiments, a seed of crystalline form I was added to initiate the generation of a suspension agent in step (b).
[0052] Pharmaceutical composition
[0053] The solid form of the crystal hydrate of the present disclosure may be used in the form of a pharmaceutical composition or formulation. Such pharmaceutical compositions may advantageously be administered to a patient by inhalation. Additionally, said pharmaceutical compositions may be administered by any acceptable route of administration, including but not limited to oral, topical (including transdermal), rectal, nasal, and parenteral administration.
[0054] Accordingly, in one embodiment of the present invention, a pharmaceutically acceptable carrier or excipient and a compound 1 The present invention provides a pharmaceutical composition comprising the crystalline hydrate (crystalline form I). Optionally, such pharmaceutical compositions may contain other therapeutic agents and / or formulation agents if preferred. When discussing compositions and their uses, the compounds of the present invention 1 The crystalline hydrate (crystalline form I) may also be referred to herein as an "active agent."
[0055] The pharmaceutical composition of the present invention is typically a compound 1It contains a therapeutically effective amount of the crystalline hydrate (crystalline form I). However, a person skilled in the art will know that a pharmaceutical composition may contain an amount exceeding a therapeutically effective amount, i.e., a bulk composition, or an amount less than a therapeutically effective amount, i.e., individual unit doses designed for multiple doses to achieve a therapeutically effective amount.
[0056] Typically, such pharmaceutical compositions will contain about 0.01 to about 95 weight% of an active agent; for example, about 0.05 to about 30 weight%; and about 0.1 weight% to about 10 weight% of an active agent.
[0057] Any conventional carrier or excipient may be used in the pharmaceutical composition of the present invention. The selection of a specific carrier or excipient, or a combination of carriers or excipients, will be determined by the mode of administration used to treat a specific patient or a type of medical condition or disease state. In this regard, the preparation of a pharmaceutical composition suitable for a specific mode of administration falls within the scope of the ordinary art in the field of pharmaceuticals. Additionally, carriers or excipients used in the pharmaceutical composition of the present invention are commercially available. As additional examples, existing formulation techniques are described in Remington: The Science and Practice of Pharmacy, 20th Edition, Lippincott Williams & White, Baltimore, Maryland (2000); and HC Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th Edition, Lippincott Williams & White, Baltimore, Maryland (1999).
[0058] Representative examples of materials that may be provided as pharmaceutically acceptable carriers include, but are not limited to, the following: sugars, e.g., lactose, glucose, and sucrose; starch, e.g., corn starch and potato starch; cellulose, e.g., microcrystalline cellulose and its derivatives, e.g., sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, e.g., cocoa butter and suppository waxes; oils, e.g., peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols, e.g., propylene glycol; polyols, e.g., glycerin, sorbitol, mannitol, and polyethylene glycol; esters, e.g., ethyl oleate and ethyl laurate; agar; buffers, e.g., magnesium hydroxide and aluminum hydroxide; alginic acid; Pyrogenic substance-removed water (pyrogen-free water); isotonic saline solution; Ringer's solution; ethyl alcohol; phosphate buffer solution; and other non-toxic, suitable substances used in pharmaceutical compositions.
[0059] A pharmaceutical composition is typically prepared by thoroughly and intimately mixing or blending an active agent with a pharmaceutically acceptable carrier and one or more optional components. The resulting uniformly blended mixture can then be formed or loaded into tablets, capsules, pills, etc., using conventional methods and equipment.
[0060] In one embodiment, the pharmaceutical composition is suitable for inhalation administration. The pharmaceutical composition for inhalation administration is typically in the form of an aerosol or powder. Such compositions are generally administered using an inhaler delivery device such as a dry powder inhaler (DPI), a metered-dose inhaler (MDI), a nebulizer inhaler, or a similar delivery device.
[0061] In a specific embodiment, the pharmaceutical composition is administered by inhalation using a dry powder inhaler. Such a dry powder inhaler typically administers the pharmaceutical composition as a free-flowing powder dispersed in the patient's airstream during inspiration. To obtain a free-flowing powder composition, the therapeutic agent is typically formulated with suitable excipients, such as lactose, starch, mannitol, dextrose, polylactic acid (PLA), polylactide-co-glycolide (PLGA), or a combination thereof. Typically, the therapeutic agent is micronized and combined with a suitable carrier to form a composition suitable for inhalation.
[0062] Representative pharmaceutical compositions used in dry powder inhalers are lactose and compounds 1 It includes a finely divided form of the crystal hydrate. Such a dry powder composition can be prepared, for example, by combining dry-ground lactose with a therapeutic agent and then dry-blending the components. The composition is then typically loaded into an inhalation cartridge or capsule for use in a dry powder dispenser or dry powder delivery device.
[0063] Dry powder inhaler delivery devices suitable for administering therapeutic agents by inhalation are disclosed in the art, and examples of such devices are commercially available. For example, representative dry powder inhaler delivery devices or products include Aeolizer (Novartis); Airmax (IVAX); ClickHaler (Innovata Biomed); Diskhaler (GlaxoSmithKline); Diskus / Accuhaler (GlaxoSmithKline); Ellipta (GlaxoSmithKline); Easyhaler (Orion Pharma); Eclipse (Aventis); FlowCaps (Hovione); Handihaler (Boehringer Ingelheim); Pulvinal (Chiesi); Rotahaler (GlaxoSmithKline); SkyeHaler / Certihaler (SkyePharma); Twisthaler (Schering-Plough); Turbuhaler (AstraZeneca); Ultrahaler (Aventis), etc.
[0064] In another specific embodiment, the pharmaceutical composition is administered by inhalation using a metered-dose inhaler. Such a metered-dose inhaler typically uses compressed propellant gas to dispense a measured amount of therapeutic agent. Thus, the pharmaceutical composition administered using a metered-dose inhaler typically comprises a suspension of the therapeutic agent within a liquefied propellant. Hydrofluoroalkanes (HFAs), such as 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoro- nAny suitable liquefied propellant comprising propane (HFA 227); and chlorofluorocarbon, e.g., CCl3F may be used. In certain embodiments, the propellant is a hydrofluoroalkane. In some embodiments, the hydrofluoroalkane formulation contains a co-solvent, e.g., ethanol or pentane, and / or a surfactant, e.g., sorbitan trioleate, oleic acid, lecithin, and glycerin.
[0065] Representative pharmaceutical compositions for the use of metered-dose inhalers are compounds 1 The composition comprises about 0.01 wt% to about 5 wt% of the crystalline hydrate (crystalline form I); about 0 wt% to about 20 wt% of ethanol; and about 0 wt% to about 5 wt% of a surfactant; and the remainder is an HFA propellant. This composition is typically prepared by adding a cooled or compressed hydrofluoroalkane to a suitable container containing the therapeutic agent, ethanol (if present), and a surfactant (if present). To prepare a suspension, the therapeutic agent is micronized and then combined with the propellant. The composition is then loaded into an aerosol canister, which typically forms part of a metered-dose inhaler device.
[0066] Metered-dose inhaler delivery devices suitable for administering therapeutic agents by inhalation are disclosed in the art, and examples of such devices are commercially available. For example, representative metered-dose inhaler devices or products include the AeroBid Inhaler System (Forest Pharmaceuticals); Atrovent Inhalation Aerosol (Boehringer Ingelheim); Flovent (GlaxoSmithKline); Maxair Inhaler (3M); Proventil Inhaler (Schering); Serevent Inhalation Aerosol (GlaxoSmithKline), etc.
[0067] In another specific embodiment, the pharmaceutical composition is administered by inhalation using a nebulizer inhaler. Such a nebulizer device typically generates a high-speed air stream to atomize the pharmaceutical composition into a mist, which is then delivered to the patient's airway. Thus, when formulated for use in a nebulizer inhaler, the therapeutic agent may be micronized or nano-grinded and combined with a suitable carrier to form a suspension.
[0068] A representative pharmaceutical composition used in a nebulizer inhaler comprises a suspension containing the crystal hydrate of the present invention in an amount of about 0.05 μg / mL to about 20 mg / mL and an excipient suitable for a nebulizer formulation. In one embodiment, the pH of the liquid is about 3 to about 8.
[0069] Nebulizer devices suitable for administering therapeutic agents by inhalation are disclosed in the art, and examples of such devices are commercially available. For example, representative nebulizer devices or products include the Respimat Softmist Inhaler (Boehringer Ingelheim); the AERx Pulmonary Delivery System (Aradigm Corp.); and the PARI LC Plus. Includes Reusable Nebulizer (Pari GmbH), etc.
[0070] In another embodiment, the pharmaceutical composition of the present invention may, alternatively, be prepared in a formulation for oral administration. A pharmaceutical composition suitable for oral administration may be in the form of a capsule, tablet, pill, lozenge, caseet, dragee, powder, granule; or a solution or suspension in an aqueous or non-aqueous liquid; or an oil-in-water or water-in-oil liquid emulsion; or an elixir or syrup, etc.; each of which may be a compound as an active ingredient 1 It contains a predetermined amount of the crystal hydrate (crystalline form I).
[0071] When intended for oral administration in the form of a solid formulation, the pharmaceutical composition of the present invention will typically comprise an active agent and one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium phosphate. Optionally or alternatively, such solid formulations may also comprise: fillers or extenders, binders, humectants, solution retarders, absorption promoters, wetting agents, absorbents, lubricants, coloring agents, and buffers. Release agents, wetting agents, coating agents, sweeteners, flavoring agents and fragrances, preservatives, and antioxidants may also be present in the pharmaceutical composition of the present invention.
[0072] Crystalline Form I can also be formulated as a sterile aqueous suspension for ocular injection. Useful excipients that may be included in such aqueous formulations include polysorbate 80, carboxymethylcellulose, potassium chloride, calcium chloride, magnesium chloride, sodium acetate, sodium citrate, histidine, α-α-trehalose dihydrate, sucrose, polysorbate 20, hydroxypropyl-β-cyclodextrin, and sodium phosphate. Benzyl alcohol may be provided as a preservative, and sodium chloride may be included to adjust tonicity. Additionally, hydrochloric acid and / or sodium hydroxide may be added to the solution to adjust the pH. The aqueous formulation for ocular injection may be prepared without preservatives.
[0073] Alternative formulations may also include controlled-release formulations, transdermal patches, and parenteral formulations. Existing excipients and methods of preparation for these alternative formulations are described, for example, in the aforementioned Remington reference.
[0074] The following non-limiting examples illustrate representative pharmaceutical compositions of the present disclosure.
[0075] Dry powder composition
[0076] Undifferentiated compounds 1 The crystalline hydrate (crystalline form I) (1 g) is blended with crushed lactose (25 g). The blended mixture is then loaded into individual blisters of a peelable blister pack in an amount sufficient to provide about 0.1 mg to about 4 mg of the compound of formula I per dose. The contents of the blisters are administered using a dry powder inhaler.
[0077] Dry powder composition
[0078] Undifferentiated compounds 1A crystalline hydrate (crystalline form I) (1 g) is blended with ground lactose (20 g) to form a bulk composition in which the weight ratio of the compound to the ground lactose is 1:20. The blended composition is packed into a dry powder inhalation device capable of delivering about 0.1 mg to about 4 mg of the compound of Formula 1 per dose.
[0079] Metered-dose inhaler composition
[0080] Undifferentiated compounds 1 The crystalline hydrate, crystalline form I (10 g) is dispersed in a solution prepared by dissolving lecithin (0.2 g) in deionized water (200 mL). The resulting suspension is spray-dried and subsequently pulverized to form a pulverized composition containing particles having an average diameter of less than about 1.5 μm. Subsequently, when the pulverized composition is administered via a metered-dose inhaler, the compound per dose 1 Load a metered-dose inhaler cartridge containing pressurized 1,1,1,2-tetrafluoroethane in an amount sufficient to provide about 0.1 mg to about 4 mg.
[0081] Nebulizer composition
[0082] A crystalline hydrate of the present disclosure, crystalline form I (25 mg), is suspended in a solution containing 1.5 to 2.5 equivalents of hydrochloric acid, and then sodium hydroxide and 3% by weight of glycerol are added to adjust the pH to 3.5 to 5.5. The suspension formulation is a compound per dose 1 It is administered using a nebulizer device that provides about 0.1 mg to about 4 mg.
[0083] Aqueous preparations for ocular injection
[0084] Each mL of sterile aqueous suspension contains 5 mg to 50 mg of compound per mL 1It contains the crystalline hydrate (crystalline form I), sodium chloride for tonicity, 0.99% (w / v) benzyl alcohol as a preservative, 0.75% sodium carboxymethylcellulose, and 0.04% polysorbate. Sodium hydroxide or hydrochloric acid may be included to adjust the pH to 5 to 7.5.
[0085] Aqueous preparations for ocular injection
[0086] The preservative-free sterile aqueous suspension contains 5 mg / mL to 50 mg / mL of a compound in 10 mM sodium phosphate, 40 mM sodium chloride, 0.03% polysorbate 20, and 5% sucrose. 1 It includes the crystal hydrate (crystal form I).
[0087] usefulness
[0088] compound 1 It was designed for the treatment of inflammatory and fibrotic diseases of the airways. In particular, the compound was designed to deliver a potent anti-cytokine activator directly to the site of action of the respiratory disease within the lungs while limiting systemic exposure.
[0089] compound 1 It was found to be a potent inhibitor of the JAK family enzymes JAK1, JAK2, JAK3, and TYK2. In addition, the compound 1 It exhibited potent inhibition of pro-inflammatory and pro-fibrotic cytokines. It has been recognized that the broad anti-inflammatory effects of JAK inhibitors can suppress normal immune cell function, potentially increasing the risk of infection. This compound has been optimized to minimize the risk of immunosuppression by limiting absorption from the lungs into the plasma.
[0090] As described in the following experimental section, compounds 1 The absorption and distribution of the compound were profiled in preclinical analyses. 1It was tested in mice and showed high concentrations in lung tissue and low absorption into plasma 5 hours after administration. 1 It was found to inhibit the effects of the pro-inflammatory cytokine IL-13 in mouse lung tissue. Specifically, the compound exhibits inhibition of IL-13-induced phosphorylation of STAT6 in lung tissue, which is in vivo ( in vivo It provides evidence of local pulmonary JAK target involvement. This effect was observed when the pro-inflammatory cytokine IL-13 was administered 4 hours after the administration of the test compound, providing additional evidence of significant retention in the lungs.
[0091] compound 1 It exhibits both potent inhibitory activity at the cellular level and significant retention in the lungs. Extensive research by the inventors has demonstrated that while it is possible to identify compounds that exhibit potent activity at the cellular level or significant retention in the lungs, it is much more difficult to discover compounds that exhibit both desirable characteristics simultaneously.
[0092] The anti-inflammatory activity of JAK inhibitors has been strongly demonstrated in preclinical models of asthma (Malaviya et al., Int. Immunopharmacol., 2010, 10 , 829-836; Matsunaga et al., Biochem. and Biophys. Res. Commun., 2011, 404 , 261-267; Kudlacz et al., Eur. J. Pharmacol , 2008 , 582Cytokines involved in asthmatic inflammation that signal via the JAK-STAT pathway include IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-11, IL-13, IL-23, IL-31, IL-27, thymic stromal lymphopoietin (TSLP), interferon-γ (IFNγ), and granulocyte-macrophage colony-stimulating factor (GM-CSF). Therefore, compounds 1 , and its crystal hydrate, crystalline form I, are expected to be useful in the treatment of inflammatory respiratory disorders, particularly asthma. Asthma is classified into low-Th2 and high-Th2 subtypes (Simpson et al, Respirology , 2006 , 11, 54-61). IL-4, IL-13, IL-5, and TSLP are associated with high-Th2 asthma, whereas IL-23 / IL-12, IL-6, IL-27, and IFN-gamma are associated with low-Th2 asthma. Based on systemic JAK inhibition profiles, compounds 1 It strongly inhibits the mediators of both high-Th2 and low-Th2 asthma. Therefore, the compound 1 Crystalline form I of is expected to be useful for the treatment of both high-Th2 asthma and low-Th2 asthma.
[0093] Inflammation and fibrosis of the lungs are characteristic of asthma as well as other respiratory diseases, e.g., chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), pneumonia, interstitial lung disease (including idiopathic pulmonary fibrosis), acute lung injury, acute respiratory distress syndrome, bronchitis, emphysema, bronchiolitis obliterans, and sarcoidosis. Therefore, compounds 1, and its crystal hydrate, crystal form I, are also expected to be useful in the treatment of chronic obstructive pulmonary disease, cystic fibrosis, pneumonia, interstitial lung disease (including idiopathic pulmonary fibrosis), acute lung injury, acute respiratory distress syndrome, bronchitis, emphysema, bronchiolitis obliterans, and sarcoidosis.
[0094] Its corresponding fluoro analogue (compound) C-1 When compared to ), compound 1 It was found to have similar JAK activity. However, as demonstrated in the assay section, it has the advantage of inducing significantly lower sulfation metabolism. This is significant because if sulfation metabolism occurs in the lungs, it can lead to a sharp decrease in exposure to the active parent compound.
[0095] compound 1 It exhibits inhibition of inflammation-related cytokines. Therefore, crystal form I will be useful for treating certain respiratory diseases, as described in detail below.
[0096] Eosinophilic airway inflammation is a characteristic feature of the disease collectively known as eosinophilic lung disease (Cottin et al., Clin. Chest. Med. , 2016 , 37(3), 535-56). Eosinophilic diseases are associated with IL-4, IL-13, and IL-5 signaling. Eosinophilic lung diseases include infections (specifically helminth infections), drug-induced pneumonia (e.g., caused by therapeutic drugs such as antibiotics, phenytoin, or l-tryptophan), fungal pneumonia (e.g., allergic bronchopulmonary aspergillosis), hypersensitivity pneumonia, and eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome). Eosinophilic lung diseases of unknown etiology include idiopathic acute eosinophilic pneumonia, idiopathic chronic eosinophilic pneumonia, hypereosinophilic syndrome, and Loeffler syndrome (L Includes ffler syndrome.
[0097] Polymorphism in the IL-6 gene is associated with increased IL-6 levels and an increased risk of developing pulmonary arterial hypertension (PAH) (Fang et al., J Am Soc. Hypertens. , 2017 , 11(3), 171-177). By demonstrating the role of IL-6 in PAH, the disease was improved in a rat model of PAH through the inhibition of the IL-6 receptor chain gp130 (Huang et al., Can J Cardiol., 2016 , 32(11), 1356.e1-1356.e10).
[0098] Cytokines such as IFNγ, IL-12, and IL-6 are associated with a wide range of non-alleiomyomatous lung diseases, such as sarcoidosis and lymphangioleiomyomatosis (El-Hashemite et al., Am. J. Respir. Cell Mol. Biol., 2005 , 33, 227-230, and El-Hashemite et al., Cancer Res. , 2004 , 64, 3436-3443). The compounds of the present disclosure have also been shown to inhibit IL-6 and IFNγ signaling.
[0099] Bronchiectasis and infiltrative lung disease are diseases associated with chronic neutrophilic inflammation.
[0100] Pathological T cell activation is important in the pathogenesis of many respiratory diseases. Autoreactive T cells play a role in bronchiolitis obliterans and organizing pneumonia (also known as COS). Similar to COS, the pathogenesis of lung transplant rejection is associated with aberrant T cell activation of recipient T cells by the transplanted donor lung. Lung transplant rejection can initially manifest as primary progenitor failure (PGD), organizing pneumonia (OP), acute rejection (AR), or lymphocytic bronchiolitis (LB), or it can develop into chronic lung allograft failure (CLAD) several years after transplantation. CLAD was previously known as bronchiolitis obliterans (BO), but it is now considered a syndrome with distinct pathological manifestations, including BO, restrictive CLAD (rCLAD or RAS), and neutrophilic allograft failure. Chronic allograft dysfunction (CLAD) is a major challenge in the long-term management of lung transplant recipients because it causes the transplanted lung to gradually lose function (Gauthier et al., Curr Transplant Rep., 2016, 3(3), 185-191). Since CLAD does not respond well to treatment, effective compounds capable of preventing or treating this pathological condition are still needed. Several JAK-dependent cytokines, such as IFNγ and IL-5, are upregulated in CLAD and lung transplant rejection (Berastegui et al, Clin Transplant. 2017, 31, e12898). Furthermore, high lung levels of CXCR3 chemokines, such as CXCL9 and CXCL10, which are downstream of JAK-dependent IFN signaling, are associated with poor prognosis in lung transplant patients (Shino et al, PLOS One, 2017, 12 (7), e0180281). Systemic JAK inhibition has been found to be effective in kidney transplant rejection (Vicenti et al., American Journal of Transplantation ,2012, 12, 2446-56). Therefore, JAK inhibitors may be effective in preventing or delaying lung transplant rejection and CLAD. Similar T-cell activation cases initiated based on lung transplant rejection are also considered a major driver of lung graft-versus-host disease (GVHD) that can occur after hematopoietic stem cell transplantation. Similar to CLAD, pulmonary GVHD is a chronic, progressive condition with extremely poor outcomes, and there are currently no approved treatments. In a retrospective, multicenter study of 95 steroid-refractory acute or chronic GVHD patients receiving the systemic JAK inhibitor ruxolitinib as salvage therapy, complete or partial remission was achieved with ruxolitinib in the majority of patients, including those with pulmonary GVHD (Zeiser et al, Leukemia , 2015, 29, 10, 2062-68). Since systemic JAK inhibition is associated with serious side effects and a small therapeutic index, there remains a need for inhaled lung-directed, non-systemic JAK inhibitors to prevent or delay lung transplant rejection or pulmonary GVHD. Compounds 1 It possesses the characteristics required to meet these needs. Recently, with the increased use of immune-checkpoint inhibitors, another T-cell mediated lung disease, immune-checkpoint inhibitor-induced pneumonia, has emerged. In cancer patients treated with these T-cell stimulators, fatal pneumonia can occur.
[0101] Mixed lymphocyte response analysis is an in-vitro analysis that mimics transplant rejection. Compound 1 It was shown to effectively inhibit IFNγ secretion.
[0102] Therefore, in one embodiment, the present disclosure provides a method for treating a respiratory disease in a mammal (e.g., human), said method comprising a compound 1Crystal hydrate (crystalline form I) or compound 1 It includes administering a therapeutically effective amount of a pharmaceutical composition containing the crystalline hydrate (crystalline form I) to a mammal (or human).
[0103] In one embodiment, the respiratory disease is selected from the group consisting of asthma, chronic obstructive pulmonary disease, cystic fibrosis, pneumonia, idiopathic pulmonary fibrosis, acute lung injury, acute respiratory distress syndrome, bronchitis, emphysema, sarcoidosis, eosinophilic disease, lung infection, helminth infection, pulmonary arterial hypertension, lymphangioleiomyomatosis, bronchiectasis, infiltrative lung disease, drug-induced pneumonia, fungal-induced pneumonia, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonia, eosinophilic granulomatosis with polyangiitis, idiopathic acute eosinophilic pneumonia, idiopathic chronic eosinophilic pneumonia, hypereosinophilic syndrome, Loeffler syndrome, obstructive bronchiolitis organizing pneumonia, pulmonary graft-versus-host disease, and immune-check-inhibitor-induced pneumonia. In some embodiments, the respiratory disease is asthma. In some embodiments, the asthma is moderate to severe asthma. In some embodiments, the asthma is mild to moderate asthma. In some embodiments, the pharmaceutical composition is administered by inhalation. In some embodiments, the asthma is high Th2 asthma. In some embodiments, the asthma is low Th2 asthma.
[0104] In one embodiment, the present disclosure provides a method for preventing or delaying lung transplant rejection in mammals (e.g., humans), said method comprising a compound 1 Crystal hydrate (crystalline form I) or compound 1The method comprises administering a therapeutically effective amount of a pharmaceutical composition comprising a crystalline hydrate (crystalline form I) to a mammal (or human). In some embodiments, the lung transplant rejection is selected from the group consisting of primary transplant dysfunction, organizing pneumonia, acute rejection, lymphocytic bronchiolitis, and chronic lung allograft dysfunction. In some embodiments, the lung transplant rejection is acute lung transplant rejection. In some embodiments, the lung transplant rejection is chronic lung allograft dysfunction. In some embodiments, the lung transplant rejection is selected from the group consisting of bronchiolitis obliterans, restricted chronic lung allograft dysfunction, and neutrophilic allograft dysfunction. In some embodiments, the pharmaceutical composition is administered by inhalation.
[0105] In addition, the present invention provides the use of crystalline form I in the manufacture of medical therapies and preparations or medicines to treat, prevent, delay, or improve diseases that can be treated with JAK inhibitors, particularly respiratory diseases and lung transplant rejection.
[0106] The present disclosure also provides a method for treating asthma in mammals, said method comprising a compound 1 Crystal hydrate (crystalline form I) or pharmaceutically acceptable carriers and compounds 1 It includes administering a therapeutically effective amount of a pharmaceutical composition containing the crystalline hydrate (crystalline form I) to a mammal.
[0107] When used for asthma treatment, compounds 1The crystalline hydrate (crystalline form I) will typically be administered as a single daily dose or multiple daily doses, and other dosage forms may also be used. The dose of the active agent per dose or the total daily dose will typically be determined by a physician in light of relevant circumstances, including the condition being treated, the selected route of administration, the actual compound administered and its relative activity, the individual patient's age, body weight and response, and the severity of the patient's symptoms.
[0108] The present disclosure also provides a method for treating respiratory diseases in mammals (including, but not limited to, diseases described herein), said method using a compound 1 Crystal hydrate (crystalline form I) or pharmaceutically acceptable carriers and compounds 1 It includes administering a therapeutically effective amount of a pharmaceutical composition containing the crystalline hydrate (crystalline form I) to a mammal.
[0109] When used for the treatment of respiratory diseases (including, but not limited to, the diseases described herein), the above compound 1 The crystalline hydrate (crystalline form I) will typically be administered once daily or multiple times daily, and other forms of administration may also be used. The dose of the active agent per dose or the total daily dose will typically be determined by a physician in light of relevant circumstances, including the condition being treated, the selected route of administration, the actual compound administered and its relative activity, the individual patient's age, weight and response, and the severity of the patient's symptoms.
[0110] Human coronaviruses are common respiratory pathogens and generally cause mild upper respiratory disease. Two highly pathogenic viruses, Severe Acute Respiratory Syndrome-associated coronavirus (SARS-CoV-1) and Middle East Respiratory Syndrome-associated coronavirus (MERS-CoV), caused severe respiratory syndrome with mortality rates exceeding 10% and 35%, respectively (Assiri et al., N Engl J Med., 2013 , 369, 407-1). The recently emerged Coronavirus Disease 2019 (COVID-19) and subsequent pandemic are causing a global medical emergency. Similar to SARS-CoV-1 and MERS-CoV, a subset of patients (about 16%) may develop severe respiratory disease manifesting as acute lung injury (ALI), which leads to ICU admissions (about 5%), respiratory failure (about 6.1%), and death (Wang et al., JAMA, 2020 , 323, 11, 1061-1069; Guan et al., N Engl J Med ., 2020 , 382, 1708-1720; Huang et al., The Lancet , 2020. 395(10223), 497-506; Chen et al., The Lancet , 2020, 395(10223), 507-13). A subgroup of COVID-19 patients appears to have a hyperinflammatory "cytokine storm" that causes acute lung injury and acute respiratory distress syndrome (ARDS). This cytokine storm can also spread to the systemic circulation, leading to sepsis and ultimately multiple organ failure syndrome. Unregulated cytokine signaling in COVID-19 is characterized by increased expression of interferon (IFN), interleukin (IL), and chemokines, which results in ALI and associated death. These hyperinflammatory responses may be regulated and treated by lung-selective systemic Janus kinase (JAK) inhibitors. Monoclonal antibodies against IL-6 (tocilizumab and sarilumab) appear to be effective in the treatment of patients with COVID-19-derived ALI (Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab, 2020 , PNAS , https: / / doi.org / 10.1073 / pnas.2005615117). Although in-vivo models of COVID-19 have not yet been published, infection with mouse-adapted 2003 SARS-CoV-1 and 2012 MERS-CoV strains, and transgenic mice expressing the human SARS-CoV-1 receptor hACE2 infected with human SARS-CoV-1, exhibit upregulation of JAK-dependent cytokines such as IFNγ, IL-6, and IL-12, as well as downstream chemokines such as chemokine (CC motif) ligand 10 (CCL10), CCL2, and CCL7 (McCray et al., J Virol. , 2007 , 81(2), 813-21; Gretebeck et al., Curr Opin Virol. 2015 , 13, 123-9.; Day et al., Virology . 2009, 395(2), 210-22. JAK inhibitors were also shown to be beneficial in mouse models of lipopolysaccharide- or ganciclovir-induced ALI (Severgnini et al., Am J Respir Crit Care Med., 2005 , 171(8), 858-67; Jin et al., Am J Physiol-Lung Cell Mol Physiol. , 2018 , 314(5), L882-92). Finally, based on clinical trial results, the JAK inhibitor baricitinib received Emergency Use Authorization (EUA) in combination with remdesivir for the treatment of COVID-19 in patients requiring oxygen supplementation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (https: / / www.fda.gov / news-events / press-announcements / coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19#:~:text=Today%2C%20the%20U.S.%20Food%20and,or%20older%20requiring%20supplemental%20oxygen%2C). In a clinical trial involving hospitalized COVID-19 patients, the combination therapy of baricitinib and remdesivir was shown to shorten the recovery time to within 29 days of the start of treatment compared to patients who received a placebo along with remdesivir.
[0111] Therefore, a compound that is a lung-selective inhaled systemic JAK inhibitor 1It may be uniquely appropriate for attenuating the cytokine storm associated with COVID-19. By delivering it to the lungs and avoiding systemic immunosuppression, it can also avoid additional infections that exacerbate mortality. This is particularly relevant for patients requiring ventilatory support. Given that comorbidities and co-infections appear to be the leading causes of death in individuals with COVID-19, inhaled drugs may be a method to avoid the immunosuppression that makes patients vulnerable to these risks.
[0112] Accordingly, the present disclosure provides a method for treating a mammal (or patient) infected with a coronavirus, e.g., SARS-CoV-1, SARS-CoV-2, and MERS-CoV, or the symptoms thereof, and said method using a compound of the present disclosure 1 Crystalline hydrate (crystalline form I) or a pharmaceutically acceptable carrier and the compound of the present disclosure 1 The present disclosure comprises administering a pharmaceutical composition comprising a crystalline hydrate (crystalline form I) to a mammal (or patient). The present disclosure also provides a method for treating ALI and / or ARDS caused by coronavirus infection (e.g., SARS-CoV-1, SARS-CoV-2, and MERS-CoV) in a mammal (or patient), wherein the method comprises the compound of the present disclosure. 1 Crystal hydrate (crystalline form I) or a pharmaceutically acceptable carrier and the compound of the present disclosure 1 It includes administering a pharmaceutical composition containing the crystal hydrate (crystalline form I) to a mammal (or patient).
[0113] The mechanism of action of JAK inhibitors is related to the treatment of nasal inflammatory diseases (Therapeutic Effects of Intranasal Tofacitinib on Chronic Rhinosinusitis with Nasal Polyps in Mice, Joo et al., The Laryngoscope , 2020, https: / / doi.org / 10.1002 / lary.29129). Also, dupilumab, which acts by blocking the IL-4 and IL-13 signaling pathways, has been approved for the treatment of chronic rhinosinusitis with nasal polyps.
[0114] Accordingly, the present invention also provides a method for treating nasal inflammatory diseases in mammals (e.g., humans), said method using the compound of the present disclosure 1 Crystalline hydrate (crystalline form I) or a pharmaceutically acceptable carrier and the compound of the present disclosure 1 The method comprises administering a pharmaceutical composition containing a crystal hydrate (crystalline form I) to a mammal (or human). In some embodiments, the nasal inflammatory disease is selected from the group consisting of chronic rhinosinusitis with or without nasal polyps, nasal polyps, sinusitis with nasal polyps, and rhinitis (non-allergic, allergic, perenial, and vasomotor rhinitis).
[0115] As a JAK inhibitor, the compound of the present disclosure 1 The crystalline hydrate (crystalline form I) of may also be useful for various other diseases. The compound of the present disclosure 1The crystalline hydrate (crystalline form I) may be useful for various inflammatory gastrointestinal indications, including but not limited to inflammatory bowel disease, ulcerative colitis (proctosigmoiditis, pancolitis, ulcerative proctitis, and left-sided colitis), Crohn's disease, collagenous colitis, lymphocytic colitis, Behcet's disease, celiac disease, immune checkpoint inhibitor-induced colitis, ileitis, eosinophilic esophagitis, graft-versus-host disease-associated colitis, and infectious colitis. Ulcerative colitis (Reimund et al., J. Clin. Immunology, 1996 , 16 , 144-150), Crohn's disease (disease (Woywodt et al., Eur. J. Gastroenterology Hepatology , 1999 , 11 , 267-276), collagenous colitis (Kumawat et al., Mol. Immunology , 2013 , 55 , 355-364), lymphocytic colitis (Kumawat et al., 2013 ), eosinophilic esophagitis (Weinbrand-Goichberg et al., Immunol. Res. , 2013 , 56 , 249-260), graft-versus-host disease-associated colitis (Coghill et al., Blood , 2001 , 117 , 3268-3276), infectious colitis (Stallmach et al., Int. J. Colorectal Dis. , 2004 , 19 , 308-315), Behcet's disease (Zhou et al., Autoimmun. Rev. , 2012 , 11, 699-704), celiac disease (de Nitto et al., World J. Gastroenterol. , 2009 , 15 , 4609-4614), immune checkpoint inhibitor-induced colitis (e.g., CTLA-4 inhibitor-induced colitis; (Yano et al., J. Translation. Med. , 2014 , 12 , 191), and ileitis (Yamamoto et al., Dig. Liver Dis. , 2008 , 40 , 253-259) is characterized by an increase in the levels of specific pro-inflammatory cytokines. Since many pro-inflammatory cytokines signal through JAK activation, the compounds disclosed in this application can alleviate inflammation and provide symptom relief. In particular, the compounds of this disclosure 1 The crystalline hydrate (crystalline form I) may be useful for inducing and maintaining remission of ulcerative colitis, and for treating gastrointestinal adverse effects in Crohn's disease, immune checkpoint inhibitor-induced colitis, and graft-versus-host disease. Accordingly, in one embodiment, the present disclosure provides a method for treating inflammatory gastrointestinal disease in mammals (e.g., humans), said method using the compound of the present disclosure 1 Crystal hydrate (crystalline form I) or pharmaceutically acceptable carriers and compounds 1 It includes administering a pharmaceutical composition containing the crystal hydrate (crystalline form I).
[0116] Atopic dermatitis and other inflammatory skin diseases are associated with an increase in pro-inflammatory cytokines dependent on the JAK-STAT pathway. Therefore, the compounds of the present disclosure 1 The crystalline hydrate (crystalline form I) is used for atopic dermatitis, alopecia areata, vitiligo, and cutaneous T-cell lymphoma (Netchiporouk et al., Cell Cycle 2014 ; 13, 3331-3335) and subtypes (Sezary syndrome, mycosis fungoides, pagetoid reticulosis, granulomatous slack skin, lymphomatoid papulosis, pityriasis lichenoides chronica, pityriasis lichenoides et varioliformis acuta), CD30+ cutaneous T-cell lymphoma, secondary cutaneous CD30+ large cell lymphoma, non-mycosis fungoides CD30- cutaneous large T-cell lymphoma, pleomorphic T-cell lymphoma, Lennert lymphoma, subcutaneous T-cell lymphoma, angiocentric lymphoma, blastic NK-cell lymphoma)), nodular prurigo (prurigo nodularis), lichen planus, primary localized cutaneous amyloidosis, bullous pemphigoid, skin manifestations of graft versus host disease, pemphigoid, discoid lupus, granuloma annulare, lichen simplex chronicus, pruritus vulvar / scrotal / anal, lichen sclerosus, post-herpetic neuralgia itch, lichen planopilaris, and foliculitis decalvans, butIt may be beneficial in numerous inflammatory or pruritic skin conditions, not limited to these. In particular, atopic dermatitis (Bao et al., JAK-STAT, 2013, 2, e24137), alopecia areata (Xing et al., Nat. Med . 2014 , 20 , 1043-1049), vitiligo (Craiglow et al, JAMA Dermatol . 2015 , 151 , 1110-1112), nodular prurigo (Sonkoly et al., J. Allergy Clin. Immunol. 2006 , 117, 411-417), lichen planus (Welz-Kubiak et al., J. Immunol. Res . 2015 , ID:854747), primary focal cutaneous amyloidosis (Tanaka et al., Br. J. Dermatol . 2009 , 161 , 1217-1224), bullous pemphigus-like disease (Feliciani et al., Int. J. Immunopathol. Pharmacol . 1999 , 12 , 55-61), and cutaneous symptoms of graft-versus-host disease (Okiyama et al., J. Invest. Dermatol. 2014 , 134 , 992-1000) is characterized by an increase in specific cytokines that transmit signals through JAK activation. Accordingly, the compounds of the present disclosure 1 The crystalline hydrate (crystalline form I) of can alleviate associated skin inflammation or pruritus induced by these cytokines. Specifically, the compound of the present disclosure 1 The crystalline hydrate (crystalline form I) is expected to be useful for treating atopic dermatitis and other inflammatory skin diseases. In one embodiment, therefore, the present disclosure provides a method for treating inflammatory skin diseases in mammals (e.g., humans), said method using the compound of the present disclosure 1The method comprises applying a pharmaceutical composition and a pharmaceutical carrier comprising a crystal hydrate (crystalline form I) of a mammal to the skin. In one embodiment, the inflammatory skin disease is atopic dermatitis.
[0117] Many eye diseases have been shown to be associated with an increase in pro-inflammatory cytokines dependent on the JAK-STAT pathway. Therefore, compounds 1The crystalline hydrate (crystalline form I) may be useful for treating a number of eye diseases, including but not limited to uveitis, diabetic retinopathy, diabetic macular edema, dry eye disease, age-related macular degeneration, and atopic keratoconjunctivitis. Specifically, (Horai and Caspi, J. Interferon Cytokine Res., 2011, 31, 733-744), diabetic retinopathy (Abcouwer, J. Clin. Cell. Immunol., 2013, Suppl 1, 1-12), diabetic macular edema (Sohn et al., American Journal of Ophthalmology, 2011, 152, 686-694), dry eye disease (Stevenson et al, Arch. Ophthalmol., 2012, 130, 90-100), and age-related macular degeneration (Knickelbein et al, Int. Ophthalmol. Clin., 2015, 55(3), 63-78) are characterized by an increase in specific pro-inflammatory cytokines that signal through the JAK-STAT pathway. Retinal vein occlusion (RVO) is a very prevalent visual impairment. The occlusion of retinal blood flow can lead to damage to retinal vascular structures, hemorrhage, and tissue ischemia. Although the causes of RVO are multifactorial, both vascular and inflammatory mediators have been found to be important (Deobhakta et al, International Journal of Inflammation, 2013, article ID 438412).Cytokines that signal via the JAK-STAT pathway, such as IL-6 and IL-13, as well as other cytokines such as MCP-1, whose production is partially induced by JAK-STAT pathway signaling, have been detected at increased levels in the ocular tissues of RVO patients (Shchuko et al, Indian Journal of Ophthalmology, 2015, 63(12), 905-911). Accordingly, the compounds of the present disclosure. 1 The crystalline hydrate (crystalline form I) can alleviate associated ocular inflammation, reverse disease progression, or provide symptom relief. Many RVO patients are treated by photocoagulation, but this is essentially a destructive therapy. Anti-VEGF agents are also used, but they are effective only in some patients. Steroid agents that reduce inflammation levels in the eye (triamcinolone acetonide and dexamethasone implants) have also been found to provide beneficial results in patients with certain forms of RVO, but they have also been shown to cause cataracts and increased intraocular pressure / glaucoma.
[0118] Accordingly, the compound of the present disclosure 1 The crystalline hydrate (crystalline form I) can alleviate associated ocular inflammation, reverse disease progression, or provide symptom relief. Accordingly, in one embodiment, the present disclosure provides a method for treating an eye disease in mammals, and said method uses the compound of the present disclosure 1 The method comprises administering a pharmaceutical composition comprising a crystalline hydrate (crystalline form I) and a pharmaceutical carrier to the eye of a mammal. The eye disease is uveitis, diabetic retinopathy, diabetic macular edema, dry eye disease, age-related macular degeneration, retinal vein occlusion, or atopic keratoconjunctivitis. In one embodiment, the method comprises a compound of the present disclosure. 1It includes administering the crystalline hydrate (crystalline form I) of the compound via intravitreal injection. 1 The crystalline hydrate (crystalline form I) can also be used in combination with one or more compounds useful for eye diseases.
[0119] compound 1 The crystalline hydrate (crystalline form I) may also be useful for treating other diseases such as other inflammatory diseases, autoimmune diseases, or cancer. The compound of the present disclosure 1 The crystalline hydrate (crystalline form I) is used for one or more cases of arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, transplant rejection, xerophthalmia, psoriatic arthritis, diabetes mellitus, insulin-dependent diabetes mellitus, motor neuron disease, myelodysplastic syndrome, pain, sarcopenia, cachexia, septic shock, systemic lupus erythematosus, leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, ankylosing spondylitis, myelofibrosis, B-cell lymphoma, hepatocellular carcinoma, Hodgkin's disease, breast cancer, multiple myeloma, melanoma, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian clear cell carcinoma, ovarian tumor, pancreatic tumor, and polycythemia vera. It may be useful for the treatment of vera), Sjoegren's syndrome, soft tissue sarcoma, sarcoma, splenomegaly, T-cell lymphoma, and thalassemia major.
[0120] Combination therapy
[0121] Compounds of the present disclosure 1The crystalline hydrate (crystalline form I) may be used in combination with one or more active agents acting through the same or different mechanisms to treat a disease. Different active agents may be administered sequentially or simultaneously as individual compositions, or as the same composition. Classes of activators useful for combination therapy include, but are not limited to, beta-2 adrenoceptor agonists, muscarinic receptor antagonists, glucocorticoid agonists, G-protein coupled receptor-44 antagonists, leukotriene D4 antagonists, muscarinic M3 receptor antagonists, histamine H1 receptor antagonists, immunoglobulin E antagonists, PDE-4 inhibitors, IL-4 antagonists, muscarinic M1 receptor antagonists, histamine receptor antagonists, IL-13 antagonists, IL-5 antagonists, 5-lipoxygenase inhibitors, beta-adrenergic receptor agonists, CCR3 chemokine antagonists, CFTR stimulators, immunoglobulin modulators, interleukin 33 ligand inhibitors, PDE-3 inhibitors, phosphoinositide-3 kinase delta inhibitors, Thromboxane A2 antagonists, elastase inhibitors, ket tyrosine kinase inhibitors, leukotriene E4 antagonists, leukotriene antagonists, PGD2 antagonists, TNF alpha ligand inhibitors, TNF binders, complement cascade inhibitors, eotaxin ligand inhibitors, glutathione reductase inhibitors, histamine H4 receptor antagonists, IL-6 antagonists, IL2 gene stimulators, immunoglobulin gamma Fc receptor IIB modulators, interferon gamma ligands, interleukin 13 ligand inhibitors, interleukin 17 ligand inhibitors, L-selectin antagonists, leukocyte elastase inhibitors, leukotriene C4 antagonists, leukotriene C4 synthase inhibitors, membrane copper amine oxidase inhibitors, metalloprotease-12 inhibitors, Metalloprotease-9 inhibitors, mite allergen modifiers, muscarinic receptor modifiers, nicotinic acetylcholine receptor agonists,Nuclear factor kappa B inhibitors, p-selectin antagonists, PDE 5 inhibitors, PDGF receptor antagonists, phosphoinositide-3 kinase gamma inhibitors, TLR-7 agonists, TNF antagonists, Abl tyrosine kinase inhibitors, acetylcholine receptor antagonists, acidic mammalian chitinase inhibitors, ACTH receptor agonists, actin polymerization modulators, adenosine A1 receptor antagonists, adenylate cyclase stimulators, adrenergic receptor antagonists, adrenocorticotrophic hormone ligands, alcohol dehydrogenase 5 inhibitors, alpha-1 antitrypsin stimulators, alpha-1 proteinase inhibitors, androgen receptor modulators, angiotensin-converting enzyme 2 stimulators, ANP agonists, Bcr protein inhibitors, beta-1 adrenergic receptors Antagonists, beta-2 adrenergic receptor antagonists, beta-2 adrenergic receptor modulators, beta-amyloid modulators, BMP10 gene inhibitors, BMP15 gene inhibitors, calcium channel inhibitors, cathepsin G inhibitors, CCL26 gene inhibitors, CCR3 chemokine modulators, CCR4 chemokine antagonists, cell adhesion molecule inhibitors, chaperonin stimulators, chitinase inhibitors, collagen I antagonists, complement C3 inhibitors, CSF-1 antagonists, CXCR2 chemokine antagonists, cytokine receptor common beta chain modulators, cytotoxic T-lymphocyte protein-4 stimulators, deoxyribonuclease I stimulators, deoxyribonuclease stimulators, dipeptidyl peptidase I inhibitors, DNA gyrase inhibitors, DP prostanoid receptor modulators, E-selectin antagonists, EGFR family tyrosine kinase receptor inhibitors, Elastin modulators, endothelin ET-A antagonists, endothelin ET-B antagonists, epoxide hydrolase inhibitors, FGF3 receptor antagonists, Fyn tyrosine kinase inhibitors, GATA 3 transcription factor inhibitors,Glucosylceramidase modulators, glutamate receptor modulators, GM-CSF ligand inhibitors, guanylate cyclase stimulators, H+ K+ ATPase inhibitors, hemoglobin modulators, heparin agonists, histone deacetylase inhibitors, histone deacetylase-2 stimulators, HMG CoA reductase inhibitors, I-kappa B kinase beta inhibitors, ICAM1 gene inhibitors, IL-17 antagonists, IL-17 receptor modulators, IL-23 antagonists, IL-4 receptor modulators, immunoglobulin G modulators, immunoglobulin G1 agonists, immunoglobulin G1 modulators, immunoglobulin epsilon Fc receptor IA antagonists, immunoglobulin gamma Fc receptor IIB antagonists, immunoglobulin kappa modulators, insulin sensitizers, interferon beta Ligand, Interleukin 1-like receptor antagonist, Interleukin 18 ligand inhibitor, Interleukin receptor 17A antagonist, Interleukin-1 beta ligand inhibitor, Interleukin-5 ligand inhibitor, Interleukin-6 ligand inhibitor, KCNA voltage-gated potassium channel-3 inhibitor, Kit ligand inhibitor, Laminin-5 agonist, Leukotriene CysLT1 receptor antagonist, Leukotriene CysLT2 receptor antagonist, LOXL2 gene inhibitor, Lyn tyrosine kinase inhibitor, MARCKS protein inhibitor, MDR-associated protein 4 inhibitor, Metalloprotease-2 modulator, Metalloprotease-9 modulator, Mineralocorticoid receptor antagonist, Muscarinic M2 receptor antagonist, Muscarinic M4 receptor antagonist, Muscarinic M5 receptor antagonist, Natriuretic peptide receptor A agonist, Natural killer cell receptor modulator, Nicotinic ACh receptor alpha 7 subunit stimulators, NK cell receptor modulators, nuclear factor kappa B modulators, opioid growth factor receptor agonists, P-glycoprotein inhibitors, P2X3 purinoceptor antagonists, p38 MAP kinase inhibitors,Peptidase 1 modulators, phospholipase A2 inhibitors, phospholipase C inhibitors, plasminogen activator 1 inhibitors, platelet activating factor receptor antagonists, PPAR gamma agonists, prostacyclin agonists, protein tyrosine kinase inhibitors, SH2 domain inositol phosphatase 1 stimulators, signal transduction inhibitors, sodium channel inhibitors, STAT-3 modulators, stem cell antigen-1 inhibitors, superoxide dismutase modulators, T-cell surface glycoprotein CD28 inhibitors, T-cell surface glycoprotein CD8 inhibitors, TGF beta agonists, TGF beta antagonists, thromboxane synthase inhibitors, thymic stromal lymphoprotein ligand inhibitors, thymosin agonists, thymosin beta 4 ligands, TLR-8 Includes agonists, TLR-9 agonists, TLR9 gene stimulators, topoisomease IV inhibitors, troponin I rapid skeletal muscle stimulators, troponin T rapid skeletal muscle stimulators, type I IL-1 receptor antagonists, type II TNF receptor modulators, ion channel modulators, uteroglobin stimulators, and VIP agonists.
[0122] Compound of the present invention 1Specific active agents that may be used in combination with the crystal hydrate (crystalline form I) are not limited to but include rosiptor acetate, umeclidinium bromide, secukinumab, metenkefalin acetate, tridecactide acetate, fluticasone propionate, alpha-cyclodextrin-stabilized sulforaphane, tezepelumab, mometasone furoate, BI-1467335, dupilumab, aclidinium, formoterol, AZD-1419, HI-1640V, and rivipansel. CMP-001, Mannitol, ANB-020, Omalizumab, Tregalizumab, Mitizax, Benralizumab, Golimumab, Roflumilast, Imatinib, REGN-3500, Masitinib, Apremilast, RPL-554, Actimmune, Adalimumab, Rupatadine, Parogrelil, MK-1029, Beclomethasone Dipropionate, Formoterol Fumarate, Mogamulizumab, Seratrodast, UCB-4144, nemiralisib, CK-2127107, fevipiprant, danirixin,Bosentan, abatacept, EC-18, duvelisib, dociparstat, ciprofloxacin, salbutamol HFA, erdosteine, PrEP-001, nedocromil, CDX-0158, salbutamol, enobosarm, R-TPR-022, lenzilumab, fluticasone furoate, vilanterol trifenatate, fluticasone propionate, salmeterol, PT-007, PRS-060, remestemcel-L, citrulline (citrulline), RPC-4046, nitric oxide, DS-102, gerilimzumab, Actair, fluticasone furoate, umeclidinium, vilanterol, AG-NPP709, Gamunex, infliximab, Ampion, acumapimod, canakinumab, INS-1007, CYP-001, sirukumab, fluticasone propionate, mepolizumab, pitavastatin, solithromycin, etanercept, ivacaftor, Anakinra, MPC-300-IV, Glycopyrronium Bromide, Aclidinium Bromide, FP-025,Risankizumab, Glycopyrronium, Formoterol Fumarate, Adipocell, YPL-001, Tiotropium Bromide, Glycopyrronium Bromide, Indacaterol Maleate, Andecaliximab, Olodaterol, Esomeprazole, Dust Mite Vaccine, Mugwort Pollen Allergen Vaccine, Vamorolone, Gefapixant, Revefenacin, Gefitinib, ReJoin, Tipelukast, Bedoradrine, SCM-CGH, SHP-652, RNS-60, Brodalumab, BIO-11006, Umeclidinium Bromide, Villanterol Trifenatate, Ipratropium Bromide, Tralokinumab, PUR-1800, VX-561, VX-371, Olopatadine, Tulobuterol, Formoterol Fumarate, Triamcinolone Acetonide, Reslizumab, Salmeterol Xinafoate, Fluticasone Propionate, Beclomethasone Dipropionate, Formoterol Fumarate, Tiotropium Bromide, Rigelizumab, RUTI, Bertilimumab, Omalizumab, Glycopyronium Bromide,SENS-111, Beclomethasone dipropionate, CHF-5992, LT-4001, Indacaterol, Glycopyronium bromide, Mometasone furoate, Fexofenadine, Glycopyronium bromide, Azithromycin, AZD-7594, Formoterol, CHF-6001, Vatepenterol, OATD-01, Olodaterol, CJM-112, Rosiglitazone, Salmeterol, Setipiprant, Inhaled interferon beta, AZD-8871, Plecanatide, Fluticasone, Salmeterol, Eicosapentaenoic acid monoglyceride, Lebrikizumab, RG-6149, QBKPN, Mometasone, Indacaterol, AZD-9898, Sodium Pyruvate, Zileuton, CG-201, Imidafenacin, CNTO-6785, CLBS-03, Mometasone, RGN-137, Procaterol, Formoterol, CCI-15106, POL-6014, Indacaterol, Beclomethasone, MV-130, GC-1112, Allergovac Depot, MEDI-3506, QBW-251, ZPL-389, Udenafil, GSK-3772847, Levocetirizine, AXP-1275, ADC-3680, timapiprant, abediterol, AZD-7594, ipratropium bromide, salbutamol sulfate, tadekinig alfa, ACT-774312, dormase alfa, iloprost, batepenterol, fluticasone furoate, alicaforsen,Ciclesonide, emeramide, arformoterol, SB-010, Ozagrel, BTT-1023, Dectrekumab, levalbuterol, pranlukast, hyaluronic acid, GSK-2292767, formoterol, NOV-14, lucinactant, salbutamol, prednisolone, ebastine, dexamethasone cipesylate, GSK-2586881, BI-443651, GSK-2256294, VR-179, VR-096, hdm-ASIT+, budesonide, GSK-2245035, VTX-1463, emedastine, Dexpramipexole, Levalbuterol, N-6022, Dexamethasone Sodium Phosphate, PIN-201104, OPK-0018, TEV-48107, Suplatast, BI-1060469, Gemilukast, Interferon Gamma, Dalazatide, Bilastine, Fluticasone Propionate, Salmeterol Xinapoate, RP-3128, Bencycloquidium Bromide, Reslizumab, PBF-680, CRTH2 Antagonist, Pranlukast, Salmeterol Xinapoate, Fluticasone Propionate, Tiotropium Bromide Monohydrate, Masilukast, RG-7990, Doxofylline, Abediterol, Glycopyronium Bromide, TEV-46017, ASM-024, Fluticasone Propionate, Glycopyronium Bromide, Salmeterol Xinapoate, Salbutamol, TA-270, Flunisolide, Sodium Chromoglycate,Epsi-gam, ZPL-521, Salbutamol, Aviptadil, TRN-157, Zafirlukast, Stempeucel, Pemirolast Sodium, Nadolol, Fluticasone Propionate + Salmeterol Xinapoate, RV-1729, Salbutamol Sulfate, Carbondioxide + Perfluorooctyl Bromide, APL-1, Dectrekumab + VAK-694, Lysine Acetylsalicylate, Zilutone, TR-4, Human Allogenic Adipose-Derived Mesenchymal Progenitor Cell Therapy, MEDI-9314, PL-3994, HMP-301, TD-5471, NKTT-120, Pemirolast, Beclomethasone Dipropionate, Trantinterol, Monosodium Alpha-Luminol, IMD-1041, AM-211, TBS-5, ARRY-502, Seratrodast, Recombinant Midismase, ASM-8, Deflazacort, Bambuterol, RBx-10017609, Ipratropium + Fenoterol, Fluticasone + Formoterol, Epinastine, WIN-901X, VALERGEN-DS, OligoG-COPD-5 / 20, Tulobuterol, Oxis Turbuhaler, DSP-3025, ASM-024, Mizolastine, Budesonide + Salmeterol, LH-011, AXP-E, Human Histamine Immunoglobulin, YHD-001, Theophylline, Ambroxol + Erdosteine,Includes ramatroban, montelukast, pranlukast, AG-1321001, tulobuterol, ipratropium + salbutamol, tranilast, methylprednisolone suleptanate, colforsin daropate, repirinast, and doxofylline.
[0123] The present invention also covers the compounds of the present disclosure. 1 A pharmaceutical composition comprising a crystalline hydrate (crystalline form I) and one or more other therapeutic agents is provided. The therapeutic agent may be selected from the class of active agents specified above and the list of specific active agents specified above. In some embodiments, the pharmaceutical composition is suitable for pulmonary delivery. In some embodiments, the pharmaceutical composition is suitable for inhalation or nebulizer administration. In some embodiments, the pharmaceutical composition is a dry powder or a liquid suspension.
[0124] In addition, in one method embodiment, the present disclosure relates to a compound of the present disclosure in a mammal. 1 A method for treating a disease or disorder in mammals is provided, comprising administering a crystal hydrate (crystallial form I) and one or more other therapeutic agents.
[0125] When used as a combination therapy, the active agent may be formulated as a single pharmaceutical composition, or the active agent may be provided as individual compositions administered simultaneously or at individual times via the same or different routes of administration. These compositions may be packaged individually or together as a kit. Two or more therapeutic agents may be administered within the kit via the same or different routes of administration.
[0126] Examples
[0127] The following synthetic and biological examples are provided to illustrate the invention and are not to be construed as limiting the scope of the invention in any way. In the following examples, the following abbreviations have the meanings below unless otherwise indicated. Abbreviations not defined below have their generally accepted meanings.
[0128] ACN = Acetonitrile
[0129] calcd = calculated
[0130] DCM = Dichloromethane
[0131] DIPEA = N,N-diisopropylethylamine
[0132] DMF = N,N-dimethylformamide
[0133] EtOAc = Ethyl acetate
[0134] h = time (hour(s))
[0135] HATU = N,N,N',N' -tetramethyl-O-(7-azabenzotriazole-1-yl)uronium
[0136] Hexafluorophosphate
[0137] IPA = Isopropyl alcohol
[0138] IPAc = Isopropyl acetate
[0139] KOAc = Potassium Acetate
[0140] MeOH = methanol
[0141] min = minutes
[0142] PdCl2(dppf) = dichloro(1,1'-bis(diphenylphosphino)-ferrocene)dipalladium(II
[0143] Pd(PPh3)4= tetrakis(triphenylphosphine)palladium(0)
[0144] RT = Room temperature
[0145] TEA = Triethylamine
[0146] TFA = Trifluoroacetic acid
[0147] THF = Tetrahydrofuran
[0148] Bis(pinacoleto)diborone = 4,4,5,5,4',4',5',5'-octamethyl-
[0149] [2,2']bi[[1,3,2]dioxaborolaniel]
[0150] Reagents and solvents were purchased from commercial suppliers (Aldrich, Fluka, Sigma, etc.) and used without further purification. The progress of the reaction mixtures was monitored by thin layer chromatography (TLC), analytical high performance liquid chromatography (analytical HPLC), and mass spectrometry. The reaction mixtures were worked up as specifically described for each reaction; typically, the reaction mixtures were purified by extraction and other purification methods, such as temperature- and solvent-dependent crystallization and precipitation. Additionally, the reaction mixtures were typically purified by column chromatography or preparative HPLC using C18 or BDS column packings and existing eluents. Typical preparative HPLC conditions are described below.
[0151] Characterization of reaction products is typically done by mass and 1 It was performed by H-NMR spectroscopy. For NMR analysis, the sample was dissolved in a deuteration solvent (e.g., CD3OD, CDCl3, or d6-DMSO), and 1H-NMR spectra were obtained using a Varian Gemini 2000 instrument (400 MHz) under standard observation conditions. Mass spectroscopic identification of the compounds was performed by the electrospray ionization method (ESMS) using an Applied Biosystems (Foster City, CA) model API 150 EX instrument or a Waters (Milford, MA) 3100 instrument combined with autopurification systems.
[0152] HPLC conditions for preparatives
[0153] Column: C18, 5 μm 21.2 x 150 mm or C18, 5 μm 21 x 250
[0154] or C14, 5 μm 21 x 150 mm
[0155] Column temperature: Room temperature
[0156] Flow rate: 20.0 mL / min
[0157] Mobile phase: A = Water + 0.05% TFA
[0158] B = ACN + 0.05 % TFA,
[0159] Injection volume: (100-1500 μL)
[0160] Detector wavelength: 214 nm
[0161] Crude compounds were dissolved in a 1:1 water-to-acetic acid solution at approximately 50 mg / mL. A 4-minute analytical scale test run was performed using a 2.1 x 50 mm C18 column, followed by a 15 or 20-minute preparative scale run using a 100 μL injection with a gradient based on the % B retention of the analytical scale test run. The exact gradient was sample-dependent. Samples with close-run impurities were identified using a 21 x 250 mm C18 column and / or a 21 x 150 mm C14 column for optimal separation. Fractions containing the target product were identified by mass spectrometry.
[0162] Analytical HPLC conditions
[0163] Method A
[0164] Column: Agilent Zorbax Bonus-RP C18, 150 x 4.60 nm, 3.5 microns
[0165] Column temperature: 40℃
[0166] Flow rate: 1.5 mL / min
[0167] Injection volume: 5 μL
[0168] Sample preparation: Dissolved in a 1:1 ACN:1 M HCl
[0169] Mobile phase: A = Water:TFA (99.95:0.05)
[0170] B = ACN:TFA (99.95:0.05)
[0171] Detector wavelengths: 254 nm and 214 nm
[0172] Gradient: 26 min Total (Hour (min) / % B): 0 / 5, 18 / 90, 22 / 90,
[0173] 22.5 / 90, 26 / 5
[0174] Method B
[0175] Column: Agilent Poroshell 120 Bonus-RP, 4.6 x 150 mm, 2.7 μm
[0176] Column temperature: 30℃
[0177] Flow rate: 1.5 mL / min
[0178] Injection volume: 10 μL
[0179] Mobile phase: A = ACN:water:TFA (2:98:0.1)
[0180] B = ACN:Water:TFA (90:10:0.1)
[0181] Sample preparation: Dissolved in mobile phase B
[0182] Detector wavelengths: 254 nm and 214 nm
[0183] Gradient: 60 min Total (Hour (min) / % B): 0 / 0, 50 / 100, 55 / 100,
[0184] 55.1 / 0, 60 / 0
[0185] Method C
[0186] Column: Agilent Poroshell 120 Bonus-RP, 4.6 x 150 mm, 2.7 μm
[0187] Column temperature: 30℃
[0188] Flow rate: 1.5 mL / min
[0189] Injection volume: 10 μL
[0190] Mobile phase: A = ACN:water:TFA (2:98:0.1)
[0191] B = ACN:Water:TFA (90:10:0.1)
[0192] Sample preparation: Dissolve in mobile phase B (0.15 mL) and then dilute with mobile phase A (0.85 mL).
[0193] Detector wavelength: 245 nm
[0194] Gradient: 46 min Total (Hour (min) / % B): 0 / 0, 25 / 50,
[0195] 35 / 100,40 / 100, 40.1 / 0, 46 / 0
[0196] Preparation Example 1: (4-(benzyloxy)-2-ethylphenyl)trifluoro-λ 4 - Boran, potassium salt I-5
[0197]
[0198] (a) 1-(benzyloxy)-3-ethylbenzene (I-2)
[0199] 3-ethylphenol in ACN (250 mL, 10 vol) (I-1) Potassium carbonate (42.0 g, 306 mmol) was added to a stirred solution of (25.0 g, 204.0 mmol) at room temperature. The resulting reaction mixture was stirred at room temperature for 15 minutes, after which benzyl bromide (24.0 mL, 204 mmol) was added dropwise. The resulting reaction mixture was stirred at room temperature for 6 hours. After the reaction was complete (TLC monitoring), the resulting reaction mixture was poured into water (1.0 L), and the compound was extracted with EtOAc (2 x 2 L). The combined organic matter was washed with cold water and brine solution, dried in sodium sulfate, filtered, and evaporated under reduced pressure. Subsequently, the crude product was purified by column chromatography on silica gel (100-200 M) using a 2% EtOAc eluent in hexane to obtain the target product. (I-2) It was obtained as a pale yellow oily compound (35.0 g, 81%). 1 H NMR (400 MHz, chloroform-d) δ 7.46-7.44 (m, 2H), 7.39 (t, J = 7.6 Hz, 2H), 7.34-7.31 (m, 1H), 7.21 (t, J = 7.6 Hz), 6.86-6.80 (m, 3H), 5.07 (s, 2H), 2.64 (q, J = 7.6 Hz, 2H), 1.24 (t, J = 7.6 Hz, 3H).
[0200] (b) 4-(benzyloxy)-1-bromo-2-ethylbenzene (I-3)
[0201] 1-(benzyloxy)-3-ethylbenzene in ACN (525 mL, 15 vol) (I-2) N-bromosuccinimide (32.0 g, 181 mmol) was added gradually over 15 minutes to an ice-cold, stirred solution of (35.0 g, 164 mmol). The resulting reaction mixture was stirred at room temperature for 1 hour. After the reaction was complete (TLC monitoring), the resulting reaction material was poured into ice-cold water (1.50 L), and the compound was extracted with EtOAc (2 x 1 L). The combined organic matter was washed with water, dried in sodium sulfate, filtered, and evaporated under reduced pressure to obtain the crude product. n-hexane (250 mL) was added to the crude material to form a slurry, which was then filtered through a sintering funnel. The mother liquor was evaporated under reduced pressure to obtain the target product. I-3 It was obtained as a pale yellow oily compound (42.0 g, 87%). 1 H NMR (400 MHz, chloroform-d) δ 7.52-7.29 (m, 7H), 6.88 (s, 1H), 6.68 (d, J = 6.0 Hz, 1H), 5.04 (s, 2H), 2.69 (q, J = 7.6 Hz, 2H), 1.20 (t, J = 7.5 Hz, 3H).
[0202] (c) 2-(4-(benzyloxy)-2-ethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan (I-4)
[0203] 4-(benzyloxy)-1-bromo-2-ethylbenzene in dioxane (440 mL) (I-3)A stirred solution of (42.0 g, 144 mmol), bis(pinacoleto) diborone (44.0 g, 173 mmol), and potassium acetate (28 g, 288 mmol) was degassed by purging with N2 (g) for 15 minutes, after which a PdCl2(dppf) DCM complex (11.0 g, 15 mmol) was added. The resulting reaction mixture was heated to 80°C for the next 16 hours. After the reaction was complete (TLC monitoring), the reaction material was filtered through a Celite bed, and the mother liquor was evaporated under reduced pressure to obtain the crude product. The crude residue was purified by column chromatography on silica gel (100-200 M) using a 1% EtOAc eluent in hexane to obtain the target product. (I-4) It was obtained as a pale yellow oily compound (32.0 g, 66%). 1 H NMR (400 MHz, chloroform-d) δ 7.74 (d, J = 8.4 Hz, 1H), 7.45-7.36 (m, 5H), 6.84-6.78 (m, 2H), 5.08 (s, 2H), 2.91 (q, J = 7.6 Hz), 1.33 (s, 12H), 1.19 (t, J = 7.6 Hz, 3H).
[0204] (d) (4-(benzyloxy)-2-ethylphenyl)trifluoro-λ 4 - Boran, potassium salt (I-5)
[0205] Compound 2-(4-(benzyloxy)-2-ethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in acetone:methanol (200 mL, 1:1 ratio, 10 vol) (I-4)A 3M solution of potassium hydrogen fluoride (23.0 g, 295 mmol, dissolved in 98.0 mL of water) was added to a stirred solution (20 g, 59.0 mmol). The resulting reaction mixture was stirred at room temperature for 16 hours. After the reaction was complete (monitored by TLC), the obtained reaction material was evaporated under reduced pressure. The solid thus obtained was dissolved in water (100 mL) and stirred at room temperature for 30 minutes. The resulting reaction material was filtered through a sintering funnel, washed with n-hexane, and dried under reduced pressure to obtain the target product. (I-5) It was provided as a white solid (14.0 g, 74%). 1 H NMR (400 MHz, chloroform-d) δ 7.43 (d, J = 7.2 Hz, 2H), 7.37 (t, J = 7.5 Hz, 2H), 7.30 (t, J = 7.1 Hz, 1H), 7.22 (d, J = 8.0 Hz), 6.58 (s, 1H), 6.53 (d, J = 7.9 Hz, 1H), 5.00 (s, 2H), 2.65 (q, J = 7.5 Hz, 2H), 1.07 (t, J = 7.4 Hz, 3H).
[0206] Preparation Example 2: 6-Benzyl 5-(tert-butyl) (S)-3-benzyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (I-11)
[0207]
[0208] (a) (S)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid, hydrochloride (I-7)
[0209] L-histidine in water (40 L, 8 vol.) (I-6)Concentrated hydrochloric acid (3.93 L, 33.75 mol) was added to an ice-cold, stirred suspension (5.0 kg, 32.14 mol), followed by the dropwise addition of formaldehyde (5.50 L, 67.5 mol, 37% aqueous solution). The resulting solution was stirred at the same temperature for 30 minutes, then heated at 80°C for 8 hours. The reaction progress was monitored using LCMS. Water was removed under reduced pressure to obtain the crude product, and the resulting crude product was stirred in toluene (20 L) for 2 hours. The organic matter was removed under reduced pressure to eliminate excess water, and the compound was dried azeotropically. The resulting material was then placed in diethyl ether (20 L) and stirred for 2 hours. The solid material was then filtered and air-dried to obtain the target product. (I-7) It was obtained as a grayish-white solid (6.50 kg, 85%). 1 H NMR (400 MHz, DO) δ 8.69 (s, 1H), 4.56 (d, J = 15.4 Hz, 1H), 4.42 (d, J = 15.5 Hz, 1H), 4.20 (dd, J = 5.5, 5.2 Hz, 1H), 3.42 (dd, J = 5.0, 17.0 Hz, 1H), 3.11 (dd, J = 10.2, 16.8 Hz, 1H).
[0210] (b) (S)-3,5-bis( tert -butoxycarbonyl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid (I-8)
[0211] (S)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid 2-hydrochloride in 1,4-dioxane (48 L, 8 vol) and water (48 L, 8 vol) (I-7)Triethylamine (12.36 L, 89 mol) was added dropwise to an ice-cold, stirred solution of (6.10 kg, 25.40 mmol), followed by the addition of di-tert-butyl dicarbonate (18.07 L, 78.74 mol, dissolved in 5 L of 1,4-dioxane) over a period of 30 minutes. The resulting reaction mixture was stirred at room temperature for the next 16 hours. After the reaction was complete (monitored by TLC & LCMS), the yellow reaction mixture was diluted with water (10 L) and washed sequentially with diethyl ether (2 x 10 L) and EtOAc (2 x 7.50 L). The organic phase was discarded. The aqueous layer was cooled and adjusted to a pH of ~3 using a 6N HCl solution; the aqueous phase was extracted with EtOAc (3 x 10 L). The combined organic materials were washed with a brine solution, dried in sodium sulfate, and concentrated under reduced pressure. The oily residue was crystallized from 30% EtOAc:hexane to produce the target product. (I-8) It was obtained as a grayish-white solid (5.1 kg, 55%). C 17 H 25 (m / z) for N3O6: [M+H]+ Calculated value 368.18 Measured value 368.21.
[0212] (c) 6-benzyl 3,5-di- tert -butyl (S)-6,7-dihydro-3H-imidazo[4,5-c]pyridine-3,5,6(4H)-triccarboxylate (I-9)
[0213] (S)-3,5-bis( in DCM (51 L, 10 vol) tert -butoxycarbonyl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid (I-8)Saturated aqueous sodium bicarbonate (41.0 L, 8 vol), tetra-butylammonium iodide (5.13 kg, 13.88 mol), and benzyl bromide (2.47 L, 20.82 mol) were sequentially added to an ice-cold solution of sodium bicarbonate (5.1 kg, 13.88 mol). The resulting reaction mixture was stirred at room temperature for the next 16 hours. After the reaction was complete (monitored by TLC & LCMS), the two-phase solution was separated. The aqueous layer was extracted with DCM (3 x 10⁻⁶ L). The combined organic materials were washed with a brine solution, dried in sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography through silica gel (100-200 M) using a 40% EtOAc eluent in hexane to obtain the target product. (I-9) was obtained as a viscous oil (4.50 kg, 72%). C 24 H 31 (m / z) for N3O6: [M+H]+ Calculated value 458.22, Measured value 458.60.
[0214] (d) 6-benzyl 5-( tert -butyl) (S)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (I-10)
[0215] 6-benzyl 3,5-di- in IPA (45 L, 10 vol) tert -butyl (S)-6,7-dihydro-3H-imidazo[4,5-c]pyridine-3,5,6(4H)-triccarboxylate (I-9)Ammonium hydroxide (36 L, 8 vol) was added dropwise to an ice-cold solution of (4.50 kg, 9.84 mol). The resulting reaction mixture was stirred at room temperature for an additional 16 hours. After the reaction was complete (monitored by TLC & LCMS), the resulting mixture was diluted with water (25 L) and then extracted with EtOAc (3 x 20 L). The combined organic materials were washed with a brine solution, dried in sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography through silica gel (100-200 M) using a 2% MeOH eluent in DCM to obtain the target product. (I-10) It was obtained as a thick viscous oil (2.70 kg, 77%). C 19 H 23 (m / z) for N3O4: [M+H]+ Calculated value 358.17, Measured value 358.33.
[0216] (e) 6-benzyl 5-( tert -butyl) (S)-3-benzyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (I-11)
[0217] 6-benzyl 5-( in DCM (32.4 L, 12 vol) tert -butyl) (S)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (I-10)Aqueous 1N sodium hydroxide (24.3 L, 9 vol) was added to an ice-cold solution of (2.70 kg, 7.55 mol), followed by the sequential addition of tetra-butylammonium iodide (2.80 kg, 7.55 mol) and benzyl bromide (0.99 L, 8.31 mol). The resulting reaction mixture was stirred at room temperature for the next 2 hours. After the reaction was complete (monitored by TLC & LCMS), the two-phase solution was separated. The aqueous layer was extracted with DCM (3 x 10⁻⁶ L). The combined organic materials were washed with a brine solution, dried in sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography on silica gel (100-200 M) using a 40% EtOAc eluent in hexane to obtain the target product. (I-11) was obtained as viscous oil (1.70 kg, 63%). C 26 H 29 (m / z) for N3O4: [M+H]+ Calculated value 448.22 Measured value 448.20.
[0218] Preparation Example 3: 6-benzyl 5-( tert -butyl) (S)-3-benzyl-2-(6-(4-(benzyloxy)-2-ethylphenyl)-1H-indazole-3-yl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (I-16)
[0219]
[0220] (a) 4-bromo-2-fluorobenzoyl chloride (I-13)
[0221] 4-bromo-2-fluorobenzoic acid in DCM (12.5 L, 15 vol) (I-12)Oxalyl chloride (0.98 L, 11.42 mol) was added dropwise to an ice-cold, stirred solution (1.25 kg, 5.71 mol). The resulting reaction mixture was stirred at the same temperature for 10 minutes. Subsequently, DMF (150 mL) was added dropwise to the reaction mixture. The resulting reaction mixture was heated to room temperature and stirred for 2 hours. After the reaction was complete (monitored by TLC), excess oxalyl chloride was removed under reduced pressure in a nitrogen atmosphere to obtain the crude product. (I-13) (1.08 kg, 80%) was obtained and used in the next step without further purification.
[0222] (b) 6-benzyl 5-( tert -butyl) (S)-3-benzyl-2-(4-bromo-2-fluorobenzoyl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (I-14)
[0223] 6-benzyl 5-( in ACN (13.6 L, 8 vol) tert -butyl) (S)-3-benzyl-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (I-11) After adding triethylamine (2.11 L, 15.2 mol) to a stirred solution (1.70 kg, 3.80 mol), 4-bromo-2-fluorobenzoyl chloride (I-13)(4.56 mol, 2 vol, in 1.08 kg, 3.4 L ACN) was added at room temperature. After the addition was complete, the color of the resulting reaction mixture changed from pale yellow to brown. The resulting reaction mixture was stirred at the same temperature for 30 minutes, and the reaction progress was monitored by TLC. The resulting reaction mixture was quenched with ice-cold water (10 L), extracted with EtOAc (3 x 5 L), and the combined organic matter was washed with a brine solution. The organic matter was dried in sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography on silica gel (100-200 M) using a 20% EtOAc eluent in hexane to obtain the target product. (I-14) (1.74 kg, 71%) was obtained. C 33 H 31 (m / z) for BrFN3O5: [M+H]+ Calculated value 648.14, measured value 648.20.
[0224] (c) 6-benzyl 5-( tert -butyl) (S)-3-benzyl-2-(6-bromo-1H-indazole-3-yl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (I-15)
[0225] 6-benzyl 5-( in THF (26.0 L, 15 vol) tert -butyl) (S)-3-benzyl-2-(4-butyl
[0226] Lomo-2-fluorobenzoyl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (I-14)Hydrazine hydrate (0.705 L, 13.4 mol) was added to a stirred solution of (1.74 kg, 2.68 mol) at room temperature. The resulting reaction mixture was heated at 60°C for 3 hours. After the reaction was complete (TLC monitoring), the resulting reaction material was poured into ice-cold water (10 L), and the compound was extracted with EtOAc (3 x 10 L). The combined organic materials were washed with brine, dried in sodium sulfate, filtered, and evaporated under reduced pressure to obtain the crude product, which was purified by column chromatography on silica gel (100-200 M) using a 20% EtOAc eluent in hexane to obtain the target product. (I-15) It was obtained as a grayish-white solid (1.12 kg, 65%). C 33 H 32 (m / z) for BrN5O4: [M+H]+ Calculated value 642.16, measured value 642.21.
[0227] (d) 6-benzyl 5-( tert -butyl) (S)-3-benzyl-2-(6-(4-(benzyloxy)-2-ethylphenyl)-1H-indazole-3-yl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (I-16)
[0228] Bis(pinacoleto)diborone (250 g, 984 mmol) was filled with propan-2-ol (1882 mL, 2.46E+04 mmol) into a 5 L three-branched single-walled flask previously etched using fluoride chemistry, and the mixture was stirred until completely dissolved. Dissolution was endothermic (-4°C). In a 4 L Erlenmeyer flask previously etched using fluoride chemistry, potassium fluoride hydrofluoride (538 g, 6891 mmol) was dissolved in water (2.306 L, 1.28E+05 mmol) to form a 3 M solution. Dissolution was endothermic (-12°C). The solution was then filtered to remove a small amount of insoluble material from the potassium fluoride hydrofluoride. Once all the solutions were completely dissolved, the contents of the Erlenmeyer flask were gradually added to a single-walled flask over a period of 15 minutes. Moderate exothermic reaction was observed (+10°C). During addition, the solution became a thick, translucent, semi-opaque gray slurry, and stirring was increased to ensure the contents were well mixed. The mixture was stirred for 1.5 hours and then filtered through a coarse glass fritted funnel (4 L, pre-etched). Filtration took 30–45 minutes to complete. The clear two-phase filtrate was discarded. The white solid was dried on the filter for 10 minutes (cracks in the cake were observed). The solid was transferred back to a clean 5 L single-walled flask with three branches and reslurried with water (1.33 L, 7.38E+04 mmol). After stirring the above slurry for 2 hours, a transparent, homogeneous hydrogel was formed.After stirring the above solution for another hour, the solid / gel was filtered using a 4 L granulated glass funnel (pre-etched). The solid was dried in the filter for 30 minutes. The solid was transferred back to a clean 5 L single-walled flask with three branches and reslurried in acetone (1.084 L, 1.48 E+04 mmol). The white / gray slurry was stirred for one hour and then filtered using a 4 L granulated glass funnel (pre-etched). Filtration took 20 minutes to complete, and the solid was then dried in the funnel for another hour. During this process, the solid was occasionally agitated to ensure uniform drying. After drying, a bright white powder remained in the filter. The above solid was dried under vacuum with low-speed nitrogen bleed at 55°C for 20 hours to obtain a fluffy white solid (200.3 g was collected).
[0229] 6-benzyl 5-(in 2-methyltetrahydrofuran (100 mL, 10 vol) tert -butyl) (S)-3-benzyl-2-(6-bromo-1H-indazole-3-yl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (I-15) (4-(benzyloxy)-2-ethylphenyl)trifluoro-λ to a stirred solution (10.0 g, 16.0 mmol) 4 - Boran, potassium salt (I-5) (8.0 g, 20 mmol) and the fluffy white solid (0.20 g) obtained above were added. The resulting reaction mixture was degassed with nitrogen gas for 30 minutes. The prepared aqueous cesium carbonate solution (20.0 g, 62.0 mmol in 60 mL of water, 6 vol) was added to the solution. The resulting reaction mixture was further degassed for 15 minutes, and then bis(di- tert0.66 g, 0.93 mmol of β-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II) was added, and the reaction mixture was evacuated under vacuum and flushed with nitrogen. The resulting reaction mixture was heated at 110°C for 20 hours. After the reaction was complete (monitored by TLC & LCMS), the resulting reaction mixture was cooled to room temperature, filtered through a Celite layer, and then further washed with EtOAc (3 x 0.5 L). The combined organic materials were washed with a 1N sodium hydroxide solution (3 x 0.5 L). The combined organic materials were then washed with brine, dried in sodium sulfate, filtered, and evaporated under reduced pressure to obtain the crude product, which was purified by column chromatography on silica gel (100-200 M) using a 20% EtOAc eluent in hexane to obtain the target product. (I-16) (As a mixture of N-benzyl positional isomers) was obtained as a pale yellow solid (8.0 g, 66%). C 48 H 47 (m / z) for N5O5: [M+H]+ Calculated value 774.36 Measured value 774.59.
[0230] Preparation Example 4: (S)-2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid, hydrochloride (I-18)
[0231]
[0232] (a) Benzyl (S)-3-benzyl-2-(6-(4-(benzyloxy)-2-ethylphenyl)-1H-indazole-3-yl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylate, hydrochloride (I-17)
[0233] 6-Benzyl 5-( tert -butyl) (S)-3-benzyl-2-(6-(4-(benzyloxy)-2-ethylphenyl)-1H-indazole-3-yl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (I-16)(1.0 g, 1.292 mmol) was dissolved in dioxane (8 mL) and water (1.5 mL), then 4 M hydrogen chloride solution in dioxane (7 mL, 28.0 mmol) was added, and the reaction mixture was stirred at room temperature for 3 hours (reaction progress was monitored by LCMS). Then, the reaction mixture was frozen, freeze-dried, and the crude product (I-17) was used directly in the following reaction (quantitative yield is assumed). C 43 H 39 (m / z) for N5O3: [M+H]+ Calculated value 674.31 Measured value 674.3.
[0234] (b) (S)-2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid, hydrochloride (I-18)
[0235] Benzyl (S)-3-benzyl-2-(6-(4-(benzyloxy)-2-ethylphenyl)-1H-indazole-3-yl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylate, hydrochloride (I-17) 0.918 g (1.292 mmol) was dissolved in 2-propanol (15 mL), 5 M aqueous hydrogen chloride solution (0.258 mL, 1.292 mmol), and water (0.25 mL) at 50 °C, and then 0.138 g (0.065 mmol) of carbonate palladium, 10% wt., 50% water was added. The reaction flask was then purged with nitrogen, a hydrogen balloon was attached, and the reaction mixture was stirred at 50 °C for 4 days while replenishing the hydrogen balloon as needed (reaction progress was monitored by LCMS). Subsequently, all solids were removed by filtration, and the resulting solution was concentrated. The residue was dissolved in a 1:1 ACN / water solution, frozen, and freeze-dried. The resulting powder (I-18) It was used without further purification (quantitative yield is assumed). C 22 H21 (m / z) for N5O3: [M+H]+ Calculated value 404.17 Measured value 404.2.
[0236] Preparation Example 5: (S)-2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid (I-19)
[0237]
[0238] (S)-2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid, HCl (I-18) (0.25 g, 0.568 mmol) was suspended in DMF (2.5 mL) and acetone (2.5 mL), after which acetic acid (0.098 mL, 1.705 mmol) and sodium cyanoborohydride (0.179 g, 2.84 mmol) were added, and the reaction mixture was stirred at room temperature for 24 hours (reaction progress was monitored by LCMS). After concentrating the reaction mixture, the crude product was purified by reverse-phase chromatography (5-70% ACN / water gradient, 50 g C18aq column) to yield the TFA salt of the title compound (149 mg, 47% yield). C 25 H 27 (m / z) for N5O3: [M+H]+ Calculated value 446.21 Measured value 446.3.
[0239] Example 1: (S)-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-yl)methanone
[0240]
[0241] (S)-2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid, TFA (I-19)(50 mg, 0.089 mmol), 3-(dimethylamino)azetidine dihydrochloride (23.20 mg, 0.134 mmol), and DIPEA (0.078 mL, 0.447 mmol) were dissolved in DMF (1.5 mL), after which HATU (51.0 mg, 0.134 mmol) was added, and the reaction mixture was stirred at room temperature for 3 hours (reaction progress was monitored by LCMS). Hydrazine (0.014 mL, 0.447 mmol) was added to cleave unwanted byproducts, and the solution was stirred at room temperature for 10 minutes. The reaction mixture was then concentrated, and the crude product was purified by preparative HPLC (5-70% ACN / water gradient, C18 column) to yield the TFA salt of the title compound (25 mg, 37% yield). C 30 H 37 (m / z) for N7O2: [M+H]+ Calculated value 528.30, Measured value 528.3. 1 H NMR (400 MHz, DMSO-d6) δ 13.09 (s, 1H), 9.40 (s, 1H), 8.27 (d, J = 8.31, 1H), 7.30 (s, 1H), 7.04 (m, 2H), 6.71 (d, J = 2.54, 1H), 6.64 (dd, J = 2.53, 8.26, 1H), 4.26 (m, 1H), 4.06 (m, 2H), 3.82 (m, 2H), 3.64 (m, 2H), 3.03 (m, 2H), 2.74 (m, 2H), 2.47 (q, J = 7.56, 2H), 2.07 (d, J = 3.69, 6H), 1.07 (m, 6H), 1.00 (t, J = 7.50, 3H).
[0242] Preparation Example 6: Benzyl ( S )-1-benzyl-2-(6-(4-(benzyloxy)-2-ethylphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-1 H -Imidazo[4,5-c]pyridine-6-carboxylate (I-21)
[0243]
[0244] Step 1
[0245] I-16 (550 g, 0.71 mol) was added to a dry, three-branched round-bottom flask. The compound was dissolved in DCM (4125 mL) at room temperature (24–25 °C) to yield a clear pale yellow solution. The solution was cooled to 0 °C over the next 30 minutes (ice-salt mixture) (the ambient temperature was -5 °C). Then, TFA (1375 mL) was slowly added over 45 minutes using a dropping funnel. The reaction was stirred at the same temperature (0 °C) for 10 minutes. The reaction mixture was heated to 30 °C and stirred at the same temperature for 1.5 hours. The reaction was monitored via TLC as well as LCMS. After the reaction was complete, the reaction mixture was evaporated under reduced pressure at 40 °C to obtain the crude material as a light brown, thick, viscous substance. Heptane stripping was performed by adding 2.5 L of heptane at each time interval and evaporating it until dry. Subsequently, the mixture was dried under high vacuum. Target product I-20 It was obtained as a thick, viscous liquid. (641 g, 100% yield, LCMS = 94.35% purity).
[0246] Step 2
[0247] 4 A° (641 g, w / w) of molecular sieves were packed into a dry, three-branched round-bottom flask, and 8 volumes (5.13 L) of acetone were added all at once under an inert gas at room temperature (25 °C). A white suspension was observed. The substance obtained in Step 1 (641 g, 0.71 mol, dissolved in 7.690 L (12 volumes) of acetone) was slowly added to the flask over 10 minutes to avoid the formation of a gummy mass within the flask. A pale yellow color was observed in the reaction mixture. CH3COOH (15.4 mL, 0.266 mol) was added dropwise at 25 °C, and the resulting reaction mixture was stirred at the same temperature for 30 minutes. A dark yellow suspension was observed. Sodium triacetoxyborohydride (297 g, 1.4 mol) was added gradually over 30 minutes at 25°C. The temperature rose from 25°C to 31°C, and the color of the reaction mixture changed from dark yellow to pale yellow. The resulting reaction mixture was stirred at 30°C for the next 30 minutes. The progress of the reaction was monitored by LCMS and TLC. After the reaction was complete, the reaction mixture was cooled to 10°C and stirred for an additional 20 minutes. The reaction mixture was then filtered through a Celite layer to remove the molecular sieve and sodium triacetoxyborohydride. The Celite layer used for filtration was washed with 10 volumes (6.41 L) of 2-Me-THF to separate the 2-Me-THF. The obtained acetone mother liquor was evaporated under reduced pressure until dry, yielding a thick, viscous liquid. The obtained viscous liquid was dissolved in 2-Me-THF (6.41 L) that had been used to wash the Celite layer. A 10% aqueous solution of NaHCO3 (~5.5 L) was added to the organic layer (2-Me-THF) to adjust the pH to approximately 7.02. At this time, slight gas generation was observed and stopped within 5 minutes. The two-phase layer and the organic layer were separated. The organic layer was further washed with water (2.0 L twice).The organic layer is dried in Na2SO4, filtered, and evaporated under reduced pressure. 95.73% HPLC purity Benzyl ( S )-1-benzyl-2-(6-(4-(benzyloxy)-2-ethylphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-1 H -Imidaz[4,5-c]pyridine-6-carboxylate (I-21) It was obtained as a pale yellow foamy solid (500 g). Eleven batches of the same scale were performed, and the obtained materials were combined. A slurry of the compound in heptane (5 volumes) was prepared and stirred at room temperature for 2 hours. The compound was filtered and washed with heptane (2 volumes). The wet cake was dried in a vacuum tray dryer for 24 hours without applying external temperature to the compound I-21 5.40 kg was obtained.
[0248] Preparation Example 7: (S)-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hi
[0249] Droxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-yl)methanone (1)
[0250]
[0251] Step 1:
[0252] Benzyl (S)-1-benzyl-2-(6-(4-(benzyloxy)-2-ethylphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylate (1,350 g, 1886 mmol) and tetrahydrofuran (2025 mL) were loaded into a dry, three-branched round-bottom flask and stirred at 25°C to obtain a homogeneous, clear yellow / orange solution. At 25°C, propan-2-ol (11,475 mL) and 6 M hydrogen chloride (aq) (1257 mL) were added to the solution and stirred to obtain a homogeneous solution. Nitrogen bubbles were used to degas the freely stirred yellow slurry for 30 minutes. 10 wt % Pd / C, 50 wt % H2O (202.5 g, 95 mmol) was added to the reactor. After shutting off the nitrogen gas, the reaction solution was purged with H2 bubbling, and the internal temperature was raised to 65°C. HPLC indicated that the reaction was complete after 210 minutes. The reaction mixture was filtered through a 10-gram Celite pad to remove a large amount of catalyst. A clear yellow solution was collected. SiliaMetS thiol (101.25 g, 953 mmol) (white solid) was added to the filtrate, and the mixture was stirred at 50°C for 1 hour to remove the remaining Pd. After 1 hour, the SiliaMetS thiol was filtered through a 0.2-micron filter to obtain a pale yellow homogeneous solution. The filtrate was subsequently concentrated to 3X (vol) and maintained at 50°C. 3 equivalents of 12M HCl (471 ml, 5657 mmol) were added to the concentrated solution at 50°C. After stirring at 50°C for 5 minutes, 2.025 grams of seed were added and the mixture was maintained at 50°C for 1 hour. The slurry became significantly thickened. 15X (vol) of acetonitrile (20250 mL) was slowly added over 120 minutes. After maintaining the batch at 50°C for 2 hours, it was cooled to 20°C for 3 hours and then maintained overnight under stirring.The slurry was then filtered, the cake was rinsed five times with ACN, and dried overnight at 50°C under high vacuum.
[0253] Once offloaded, the cake provided a pale orange solid of (S)-2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid, 2HCl (850 g, 1640 mmol, 87% yield).
[0254] compound I-21 Performing a similar plan for 1.115 kg of compounds I-22 An additional 700g was obtained. The two obtained lots were combined.
[0255] Step 2:
[0256] N,N-dimethylazetidin-3-amine, 2HCl (432 g, 2497 mmol) and N,N-dimethylacetamide (3750 ml, 4.00E+04 mmol) were loaded into a jacketed reactor at 20°C. DIPEA (2699 ml, 1.55E+04 mmol) was added over approximately 5 minutes at 20°C. The mixture was stirred at 20°C for 15 minutes to obtain a hazy solution, which was then cooled to 10-15°C while stirring at 200 rpm. (S)-2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid, 2.2HCl (1250g, 2378 mmol) was added to the batch while maintaining the temperature below 20℃.
[0257] An exothermic reaction was observed during the addition (an exothermic reaction of approximately 7°C was observed). A slurry was obtained and stirred at 15–25°C for about 15 minutes. After 15 minutes, a thin slurry was still observed. With an internal temperature of 17°C, HATU (994 g, 2615 mmol) was added over approximately 5 minutes while mixing at 350 rpm at 20 ± 5°C. During the addition, the temperature rose to 22°C. A thin slurry was obtained after the addition of HATU. The batch was maintained at 20–25°C and stirred at 215 rpm for 2 hours until the reaction was complete. Upon completion of the reaction, the batch temperature was maintained below 30°C, and a 1M aq. HCl (4993 ml, 4993 mmol) (5°C) solution diluted with 1 volume of pre-mixed, cooled water (1.25 L) was added.
[0258] 5 volumes (6,250 mL) of isopropyl acetate were charged into the batch and the mixture was stirred for 15 minutes. Stirring was stopped. The aqueous acid layer was separated and transferred to a reactor. The organic layer was discarded. The pH of the aqueous layer was adjusted to 4-5.0. 5 volumes (6,250 mL) of isopropyl acetate were added to the batch and stirring was performed at 20°C for 15 minutes. The mixture was maintained at 20°C. The aqueous acid layer was separated and transferred to a reactor. The organic layer was discarded. 5 volumes (6,250 mL) of isopropyl acetate were added to the batch and stirred at 20°C for 15 minutes, then maintained at 20°C. The aqueous acid layer was separated and transferred to a reactor. The organic layer was discarded. The aqueous acid layer was stored overnight at 20°C. 30 volumes (37.5 kg) of water were charged into the reactor. Sodium bicarbonate (1238 g, 1.47E+O4 mmol) was added, and the mixture was stirred until completely dissolved. Stirring was stopped, and the solution was maintained at 20°C overnight. 10 volumes (12,500 mL) of 2-methyltetrahydrofuran were added to the aqueous solution while stirring. An exothermic reaction was observed. The internal temperature was 20 +The temperature was adjusted to 5°C. The aqueous acid layer was added to the reactor over approximately 10 minutes. A mild exothermic reaction of 1°C was observed. The mixture was stirred at 20°C for approximately 15 minutes and then maintained at 20°C. The bottom aqueous layer was removed and added to the reactor. The organic layer was removed, and extraction was performed by filling with 5 volumes (6,250 mL) of 2-methyltetrahydrofuran and mixing at 20°C for approximately 15 minutes. The combined aqueous layer was concentrated to 3 volumes (3.75 L) using a rotovap at a bath temperature of 50°C. 10 volumes (12,500 mL) of 2-methyltetrahydrofuran were added, and the mixture was concentrated to 3 volumes (3.75 L) using a rotovap at a bath temperature of 50°C. Acetonitrile (2.00E+04 mL) was added to a 25 L jacketed reactor and mixed at 215 rpm while adjusting the internal temperature to 0–5 °C. The concentrated batch (approx. 3.75 L) was added to the cooled acetonitrile at 0–5 °C over approximately 1 hour. The mixture was aged overnight at 0 °C while mixing at 215 rpm. It was filtered, and the cake was washed with 4 volumes of pre-cooled acetonitrile (5,000 mL) at 0 °C. The cake was dried in a filter under N2 gas pressure over 2 hours. . Wet cake under strong vacuum (with slight N2 purging) ) Dry overnight at 50℃ ( S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H -indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-yl)methanone (1150 g, 2179 mmol, 92% yield) was obtained as an amorphous solid. A second batch of the material was prepared in the same manner, yielding 1036 g ( S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H-Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-yl)methanone was provided as an amorphous solid (confirmed by PXRD) and two batches were combined.
[0259] Example 2: ( S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H -Imidaz[4,5-c]pyridine-6-yl)methanone crystal hydrate (crystalline form I)
[0260] ( S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H -imidazo[4,5-c]pyridin-6-yl)methanone (95 g, 180 mmol) was dissolved in 1 M HCl (aq) (950 mL) and isopropyl acetate (950 mL) at 30°C. The batch was maintained at 30°C for 30 minutes, and then the layers were separated. This was repeated three times, always retaining the bottom aqueous layer and discarding the isopropyl acetate layer. After the isopropyl acetate extraction of the fourth aqueous layer, 2-methyltetrahydrofuran (950 mL, 9419 mmol) was added, and the pH was then adjusted to 7.5 with sufficient 10% sodium bicarbonate. The mixture was stirred for 30 minutes, and the layers were separated. The aqueous layer was extracted with 2-methyltetrahydrofuran (250 mL). The 2-methyltetrahydrofuran layers were combined. A solvent swap from 2-methyltetrahydrofuran to acetonitrile was performed to precipitate the product from the solution. After filtration and drying, the cake weighs 89 grams ( S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H-Imidazō[4,5-c]pyridine-6-yl)methanone was provided. This solid (89 g) was taken into 445 mL of methanol. After stirring until completely dissolved, the batch was filtered through a 0.2 μm filter. The filtrate was then heated to an internal temperature of 55°C and maintained at this temperature for 60 minutes while stirring. The solution became slightly turbid as a small precipitate began to form. The temperature was then cooled linearly at a rate of 0.2°C / min until the final internal temperature reached 15°C and maintained at 15°C for 8 hours. At this point, the batch had thickened considerably, and the slurry was filtered under a nitrogen blanket using a strong vacuum. After offloading the wet cake, it was dried for 18 hours under a strong vacuum (28 mm Hg) in a vacuum oven set to 65°C. The dry cake was subsequently off-loaded and allowed to equilibrate with the ambient humidity and temperature to provide a final white to grayish-white crystalline cake of (S)-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-yl)methanone hydrate crystalline form I (75 g, 140 mmol, 78% yield).
[0261] Example 3: Crystalline hydrate of (S)-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-yl)methanone (Compound 1), crystalline form I
[0262] (S)-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 obtained in Preparation Example 7) in a 20L jacketed reactor H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H -Imidazō[4,5-c]pyridin-6-yl)methanone (compound 12186 g (4143 mmol) was added, followed by treatment with methanol (10930 mL). The obtained slurry was stirred and heated to 55°C to provide a clear, homogeneous solution. The solution was maintained at 55°C for 30 minutes and seeded (with 2.186 g of the material obtained in the previous example). The solution was maintained at 55°C for an additional 1 hour. Crystallization and thickening occurred. The mixture was then cooled to 10°C over 450 minutes. The batch was internally maintained at 10°C for 12 hours and then filtered. The wet cake was washed with methanol (2186 mL) pre-cooled to 5°C. The cake was dried in a filter dryer under vacuum using nitrogen purging and a heated jacket set to 55°C. The cake was maintained under these drying conditions for 19 hours. Subsequently, the cake was off-loaded and spread onto a drying tray and allowed to equilibrate with ambient RH conditions over 30 hours to provide the crystal hydrate, crystalline form I, of (S)-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-yl)methanone (1411.6 g, 2587 mmol, 62.4% yield) as a grayish-white to pale yellow solid.
[0263] Example 4: Crystalline hydrate of (S)-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-yl)methanone (Compound 1), crystalline form I
[0264] A crude obtained by a method similar to that shown in Example 2 ( S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H -Imidazō[4,5-c]pyridin-6-yl)methanone (compound 11.250 mL of methanol was added to 250 g of the sample, and the resulting slurry was heated to 55°C for 30 minutes to provide a homogeneous solution. The solution was filtered through a 0.2 μm filter. The filtrate was stirred at 55°C for 3 hours, and crystallization began. The temperature of the resulting mild slurry was adjusted to 5°C for approximately 250 minutes. The thickened slurry was stirred overnight at 5°C. Subsequently, the solid was separated using a pressure filter. The filter cake was washed with 250 mL of pre-cooled methanol at 5°C and then dried overnight under high vacuum at 55°C to provide 180 g of crystalline material. 900 mL of methanol was added to the 180 g of the obtained crystalline material. The temperature of the stirred slurry was adjusted to 55°C for approximately 30 minutes. The slurry was stirred at 55°C for approximately 3 hours. Subsequently, the temperature of the slurry was adjusted to 5-15°C for approximately 200 minutes. The slurry was stirred for approximately 2 more hours at 5-15°C. The solid was separated using a pressure filter under inert conditions. The filter cake was washed with methanol (300 mL) pre-cooled to 5-15°C, and then dried in a vacuum oven at 55-65°C for approximately 12 hours under high vacuum. The dried cake was maintained at ambient temperature, pressure, and relative humidity for approximately 12 hours to obtain 165.7 g ( S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H - A crystalline monohydrate (crystalline form I) of imidazo[4,5-c]pyridine-6-yl)methanone was provided as a grayish-white to pale yellow solid with a purity of 97.7% based on HPLA data.
[0265] Example 5: Crystalline hydrate of (S)-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-yl)methanone (Compound 1), crystalline form I
[0266] (S)-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-yl)methanone was prepared and obtained in a manner similar to that shown in Step 2 of Preparation Example 7 above. The obtained solid (0.100 g, 0.183 mmol) was dissolved in ethanol (0.5 ml, 0.183 mmol) over 5 hours at 50°C, at which time a slurry was formed. The slurry was filtered at the corresponding temperature under inert conditions, dried in an oven at 60°C under vacuum for 12 hours, and then equilibrated at ambient room temperature and pressure for 12 hours to yield crystalline form I (0.06 g).
[0267] Examples 6-10: Characteristics of crystalline form
[0268] ( S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H -Imidazō[4,5-c]pyridin-6-yl)methanone (compound 1 Samples of the crystalline hydrate, crystalline form I, were analyzed through powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic water adsorption (DMS), and single crystal X-ray diffraction.
[0269] Example 6 Powder X-ray Diffraction
[0270] The powder X-ray diffraction pattern of Fig. 1, Cu- with an output voltage of 45 kV and a current of 40 mA KαData were obtained using a Bruker D8-Advance X-ray diffractometer equipped with a Lynxeye 1D detector using radiation (λ = 1.54051 Å). The instrument was operated in a Bragg-Brentano geometry with incident, divergent, and scattering slits set to maximize intensity in the sample. For measurements, a small amount of powder (5–25 mg) was gently pressed into the sample holder to form a smooth surface and exposed to X-rays. The sample was scanned in 2θ-2θ mode at 2° to 35° for a total scan time of 1 hour, with a step size of 0.02° and a scan rate of 2 seconds per step. Data acquisition was controlled by Bruker DiffracSuite measurement software and analyzed with Jade software (version 7.7). The observed PXRD 2θ peak positions and d - The gap is a compound 1 The crystal hydrate, crystal form I, is presented in Table 1.
[0271]
[0272] Example 7: Thermal Analysis
[0273] Differential Scanning Calorimetry (DSC) was performed using the TA Instruments Model Discovery DSC. Data were collected using TRIOS software and analyzed using TA Instruments Universal Analysis software. A sample of the crystalline form was accurately weighed into an aluminum pan covered with a TZero sealed pinhole lid. The sample was initially cooled to -20°C and then heated from -20°C to 250°C using a linear heating ramp at 10°C / min. A representative DSC thermal analysis of crystalline form I is shown in Figure 2.
[0274] Thermogravimetric analysis (TGA) measurements were performed using a TA Instruments Model Discovery TGA module equipped with high-resolution capabilities. Data were collected using TA Instruments TRIOS software and analyzed using TA Instruments Universal Analysis software. Weighed samples were placed in a platinum pan and scanned from ambient temperature to 260°C at a heating rate of 10°C per minute. The balance and furnace chamber were purged with a nitrogen flow during use. Representative TGA traces of crystalline form I are shown in Figure 3. A weight loss of approximately 3.4% was observed between 27°C and 100°C, which corresponds to dehydration of the monohydrate form.
[0275] Example 8: Dynamic moisture adsorption evaluation
[0276] Dynamic Moisture Adsorption (DMS) measurements were performed using a VTI atmospheric microbalance, SGA-100 system (VTI Corp., Hialeah, FL 33016). Weighed samples were used, and the humidity was set to the lowest possible value (approaching 0% RH) at the start of the analysis. The DMS analysis consisted of two cycles of adsorption and desorption at a scan rate of 5% RH / step over a humidity range of 5% RH to 90% RH, following an initial drying phase (~0% RH) for 16 hours. The DMS run was performed isothermally at 25 °C. Representative DMS traces of crystalline form I are shown in Fig. 4.
[0277] Example 9: Single Crystal X-ray Diffraction
[0278] A compound with dimensions of 0.28 x 0.11 x 0.02 mm 1 Crystals of the crystal hydrate (crystal form I) were placed on glass fibers.
[0279] Data were collected on a Rigaku Atlas CCD diffractometer equipped with an Oxford Cryosystems Cobra cooling unit. Data were collected using Cu Kα radiation, and the structure was analyzed and refined using Bruker AXS SHELXTLsuite crystallization software. Hydrogen atoms attached to carbons were geometrically arranged and could be refined using the riding isotropic displacement parameter. Hydrogen atoms attached to heteroatoms were located on the difference Fourier map and could be freely refined using the isotropic displacement parameter. The unit cell parameters, along with the crystal system and space group, are shown in Table 2 below. The data indicate that crystal form I is a monohydrate.
[0280]
[0281] Example 10: Stability Study
[0282] Samples of crystalline form I stored under accelerated conditions of 25 °C and 60% relative humidity (RH) and 40 °C and 75% relative humidity (RH) were compounds 1 The content and impurity profiles were analyzed by HPLC, and the results are shown in Tables 3 and 4.
[0283] RRT = Relative Retention Time (Compound 1 (regarding)
[0284] LOQ = Limit of Quantification (0.05% a / a), only peaks above LOQ are reported
[0285]
[0286]
[0287] Crystalline form I exhibited excellent stability under these conditions.
[0288] Preparation Example 8: 2-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan
[0289]
[0290] (a) 1-(benzyloxy)-4-bromo-5-ethyl-2-fluorobenzene
[0291] K2CO3 (31.55 g, 228.3 mmol) was added to a solution of 4-bromo-5-ethyl-2-fluorophenol (20 g, 910.32 mmol) in ACN (250 mL), followed by the dropwise addition of benzyl bromide (13.10 mL, 109.58 mmol). The resulting reaction mixture was stirred at 80°C for 2 hours. The aqueous layer was extracted with EtOAc (three times), combined with brine, and washed with brine. The organic layer was dried with Na2SO4 and evaporated under reduced pressure to yield the title intermediate as a pale yellow oily liquid. ( It was provided as 25 g (89% yield). 1 1H NMR (400 MHz, Chloroform- d ) δ 7.48 - 7.30 (m, 5H), 7.27 (d, J = 10.5 Hz, 1H), 6.87 (d, J = 8.7 Hz, 1H), 5.12 (s, 2H), 2.66 (q, J = 7.5 Hz, 2H), 1.16 (t, J = 7.5 Hz, 3H).
[0292] (b) 2-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan
[0293] Bis(pinacoleto)diborone (15.40 g, 60.67 mmol) and KOAc (11.9 g, 121.35 mmol) were added to a solution of the product of the previous step (12.5 g, 40.45 mmol) in dioxane (100 mL). After purging the reaction mixture with nitrogen for 15 minutes, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1.65 g, 2.023 mmol), a complex with dichloromethane, was added. The resulting reaction mixture was stirred, heated at 110°C for 3 hours, filtered through Celite, and the residue was washed with EtOAc. The filtrate was diluted with an excess amount of EtOAc (200 mL), washed with water (100 mL) followed by brine (100 mL), dried with sodium sulfate, and concentrated under vacuum to obtain a crude product, which was purified by (100-200) silica gel column chromatography eluted with 3-5% EtOAc:hexane to provide the desired product as a grayish-white solid (9.50 g, 66% yield). 1 1H NMR (400 MHz, Chloroform- d ) δ 7.54 - 7.27 (m, 6H), 6.81 (d, J = 7.9 Hz, 1H), 5.16 (s, 2H), 2.84 (q, J = 7.5 Hz, 2H), 1.32 (s, 12H), 1.14 (t, J = 7.5 Hz, 3H).
[0294] Preparation Example 9: 6-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-1-(tetrahydro-2 H -pyran-2-yl)-3-(trimethylstanyl)-1 H -Indazole
[0295]
[0296] (a) 6-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-1-(tetrahydro-2 H -Evacuation-2-day)-1 H -Indazole
[0297] 6-bromo-1-(tetrahydro-2) in DMF:H2O (480:120 mL) H -Evacuation-2-day)-1 H K3PO4 (94.64 g, 446.86 mmol) was added to a solution of indazole (50 g, 178.57 mmol) and 2-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (76.3 g, 214.29 mmol). The reaction mixture was degassed with nitrogen for 15 minutes, then Pd(PPh3)2Cl2 catalyst (6.26 g, 8.93 mmol) was added, the mixture was degassed again by stirring with nitrogen for 5 minutes, and heated at 100-110°C for 5 hours. The reaction mixture was filtered through Celite, and the residue was washed with EtOAc. The filtrate was diluted with EtOAc, washed with cold water and brine, dried over sodium sulfate, and concentrated under vacuum to obtain the crude product, which was purified by flash column chromatography to provide the title intermediate as a white solid (65 g, 86% yield). C 27 H 27 Regarding FN2O2 ( m / z ): [M+H] + Calculated value 431.21, Measured value 431.46. 1 1H NMR (400 MHz, Chloroform- d ) δ 8.06 - 7.98 (m, 2H), 7.70 (d, J = 8.2 Hz, 1H), 7.51 - 7.32 (m, 5H), 7.08 (dd, J = 809.6, 8.3 Hz, 1H), 7.03 (d, J = 11.9 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 5.76 - 5.64 (m, 1H), 5.20 (s, 2H), 4.04 (d, J = 10.1 Hz, 1H), 3.72 (t, J = 9.7 Hz, 1H), 2.52 (q,J = 7.5 Hz, 2H), 2.22 - 2.02 (m, 3H), 1.80 - 1.71 (m, 3H), 1.06 (t, J = 7.5 Hz, 3H).
[0298] (b) 6-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-1 H -Indazole
[0299] Concentrated HCl (120 mL) was added to a solution of the product of the previous step (65 g, 151.16 mmol) in methanol (700 mL), and the resulting solution was heated at 60-65°C for 3 hours, cooled to room temperature, and concentrated under vacuum. The residue was dissolved in EtOAc and washed with a saturated aqueous solution of NaHCO3 and water. The organic layer was dried with anhydrous Na2SO4 and concentrated under vacuum to provide the title intermediate as a white solid (52 g, 99% (Cho)). 1 1H NMR (400 MHz, Chloroform- d ) δ 8.13 (s, 1H), 7.77 (d, J = 8.3 Hz, 1H), 7.59 - 7.30 (m, 6H), 7.10 (d, J = 8.3 Hz, 1H), 7.01 (d, J = 11.8 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 5.21 (s, 2H), 2.53 (q, J = 7.5 Hz, 2H), 1.05 (t, J = 7.5 Hz, 3H).
[0300] (c) 6-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-3-iodo-1 H -Indazole
[0301] 6-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-1 in DMF (400 mL) HKOH (36.2 g, 647.39 mmol) was added to a solution of indazole (56 g, 161.18 mmol) and the mixture was stirred for 5 minutes. A solution of iodine (82.2 g, 323.69 mmol) in DMF (100 mL) was slowly added at 0°C and stirred at room temperature for 30 minutes, diluted with water (3 x 150 mL), and extracted with EtOAc (3 x 200 mL). The organic layer was washed with an aqueous solution of saturated sodium metabisulfite (3 x 200 mL) and water (400 mL), dried with anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product, which was purified by flash column chromatography to provide the title intermediate as a brown semi-solid (64 g, 84% yield). 1 1H NMR (400 MHz, Chloroform- d ) δ 10.49 (s, 1H), 7.57 - 7.32 (m, 7H), 7.16 (d, J = 8.3 Hz, 1H), 7.04 - 6.91 (m, 2H), 5.20 (s, 2H), 2.51 (q, J = 7.4 Hz, 2H), 1.04 (t, J = 7.5 Hz, 3H).
[0302] (d) 6-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-3-iodo-1-(tetrahydro-2 H -Evacuation-2-day)-1 H -Indazole
[0303] p-toluenesulfonic acid (4.84 g, 25.423 mmol) was added to an ice-cold solution of the product from the previous step (60 g, 127.12 mmol) in DCM (700 mL), followed by the dropwise addition of 3,4-dihydro-2H-pyran (17.43 mL, 190.68 mmol). The reaction mixture was stirred overnight at room temperature, diluted with DCM, and washed with a saturated aqueous solution of NaHCO3 and brine. The organic layer was dried with anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product, which was purified by flash chromatography (silica gel) to provide the title intermediate as a grayish-white solid (64 g, 91% yield). C 27 H 26 Regarding FIN2O2 ( m / z ): [M+H] + Calculated value 557.10 Actual value 557.30. 1 1H NMR (400 MHz, Chloroform- d ) δ 7.56 - 7.31 (m, 7H), 7.14 (d, J = 8.3 Hz, 1H), 7.01 (d, J = 11.8 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 5.68 (d, J = 9.3 Hz, 1H), 5.20 (s, 2H), 4.08 - 3.99 (m, 1H), 3.77 - 3.64 (m, 1H), 2.50 (q, J = 7.2 Hz, 2H), 2.23 - 1.97 (m, 3H), 1.81 - 1.68 (m, 3H), 1.06 (t, J = 7.4 Hz, 3H).
[0304] (e) 6-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-1-(tetrahydro-2 H -pyran-2-yl)-3-(trimethylstanyl)-1 H -Indazole
[0305] 6-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-3-iodo-1-(tetrahydro-2) in toluene (150 mL)H -Evacuation-2-day)-1 H Hexamethylditin (9.2 mL, 43.17 mmol) was added to a solution of indazole (20 g, 35.97 mmol). The reaction mixture was degassed with nitrogen for 20 minutes, then tetrakis (2.0 g, 1.80 mmol) was added, stirred at 100°C for 2 hours, cooled to room temperature, filtered through Celite, and the residue was washed with EtOAc. The filtrate was concentrated and purified by column chromatography (neutral alumina phase) eluted with 2 to 5% EtOAc:hexane to provide the title compound (17.50 g, 82% yield). C 30 H 35 Regarding FN2O2Sn ( m / z ): [M+H] + Calculated values 595.17, 593.17. Measured values 595.49, 593.55. 1 1H NMR (400 MHz, Chloroform- d ) δ 7.68 (d, J = 8.0 Hz, 1H), 7.57 - 7.29 (m, 6H), 7.13 - 7.00 (m, 2H), 6.96 (d, J = 8.4 Hz, 1H), 5.81 - 5.68 (m, 1H), 5.21 (s, 2H), 4.13 - 4.00 (m, 1H), 3.81 - 3.66 (m, 1H), 2.54 (q, J = 7.3 Hz, 2H), 2.23 - 2.00 (m, 2H), 1.87 - 1.59 (m, 4H), 1.08 (t, J = 7.5 Hz, 3H), 0.47 (s, 9H).
[0306] Preparation Example 10: 5-( tert -butyl) 6-methyl ( S )-2-iodo-3-((2-trimethylsilyl)ethoxy) methyl)- 3,4,6,7-tetrahydro-5 H -Imidazo[4,5-c]pyridine-5,6-dicarboxylate
[0307]
[0308] (a) ( S )-4,5,6,7-tetrahydro-3 H -Imidazo[4,5-c]pyridine-6-carboxylic acid
[0309] Concentrated HCl (29 mL) was added dropwise at 0 °C to a stirred suspension of L-histidine (50 g, 322.24 mmol) in water (420 mL), followed by the addition of formaldehyde (55 mL, 676.72 mmol) at 0 °C. The resulting reaction mixture was stirred for 30 minutes, then heated at 75 °C for 6 hours and concentrated. The resulting crude material was stirred with diethyl ether for 2 hours, filtered, and washed with IPA:THF (100:300 mL) to yield the HCl salt of the title intermediate as a grayish-white solid (75 g 99% yield (crude)). (m / z) for C7H9N3O2: [M+H] + Calculated value 168.07 Measured value 168.17.
[0310] (b) methyl ( S )-4,5,6,7-tetrahydro-3 H -Imidaz[4,5-c]pyridine-6-carboxylate
[0311] SOCl2 (45.6 mL, 625 mmol) was added dropwise at 0°C to a stirred solution of the product of the previous step (75.0 g, 312.5 mmol) in methanol (1500 mL), stirred at room temperature for 16 hours, and then heated to reflux (70°C) for 1 hour. The solvent was removed by distillation, and the crude product was triturated with methanol followed by diethyl ether to provide the crude HCl salt of the title intermediate as a grayish-white solid (crude 80 g). 1 ¹H NMR (400 MHz, DMSO- d 6) δ 9.05 (s, 1H), 4.71 (dd, J = 9.4, 5.2 Hz, 1H), 4.36 (d, J = 15.5 Hz, 1H), 4.30 (d, J= 15.6 Hz, 1H), 3.82 (s, 3H), 3.44 - 3.21 (m, 2H).
[0312] (c) 5-( tert -butyl) 6-methyl ( S )-3,4,6,7-tetrahydro-5 H -Imidazo[4,5-c]pyridine-5,6-dicarboxylate
[0313] Di-tert-butyl dicarbonate (172 mL, 787.48 mmol) was added at 0 °C to a stirred solution of the previous step product (80.0 g, 314.96 mmol) in methanol (1000 mL), followed by DIPEA (282 mL, 1574 mmol). The reaction mixture was stirred at room temperature for 16 hours, after which liquid NH3 (150 mL, 25% in water) was added and the reaction mixture was stirred again at room temperature for 16 hours. The methanol was removed by distillation, and the residue was extracted in DCM (3 x 200 mL). The combined organic extract was dried over anhydrous Na2SO4, concentrated, and purified by flash chromatography (100-200 mesh silica gel) eluted with 5% MeOH:DCM to yield the title intermediate (41 g, 46% yield). C 13 H 19 Regarding N3O4 ( m / z ): [M+H] + Calculated value 282.14 Measured value 282.21. 1 ¹H NMR (400 MHz, DMSO- d 6) δ 11.85 (s, 1H), 7.50 (s, 1H), 5.18 (dd, J = 49.3, 5.1 Hz, 1H), 4.51 (t, J = 14.2 Hz, 1H), 4.09 (dd, J = 43.9, 16.1 Hz, 1H), 3.59 (s, 3H), 3.08 (d, J = 15.5 Hz, 1H), 2.94 (d, J= 15.1 Hz, 1H), 1.45 (s, 9H).
[0314] (d) 5-( tert -butyl) 6-methyl ( S )-2-iodo-3,4,6,7-tetrahydro-5 H -Imidazo[4,5-c]pyridine-5,6-dicarboxylate
[0315] In a solution of the product of the previous step (41.0 g, 145.9 mmol) in THF (500 mL) N - Iodosuccinimide (66.0 g, 291.8 mmol) was added at 0°C, and the resulting solution was stirred at room temperature for 4 hours, diluted with water, and extracted with ethyl acetate. The organic portion was washed with a 10% sodium thiosulfate solution (3 x 200 mL). The combined organic layer was dried with anhydrous sodium sulfate and concentrated to obtain 60 g (cru) of the title compound, which was used in the next step without further purification. C 13 H 18 Regarding IN3O4 ( m / z ): [M+H] + Calculated value 408.03, Measured value 408.31. 1 ¹H NMR (400 MHz, DMSO- d 6) δ 12.48 (s, 1H), 5.34 - 4.97 (m, 1H), 4.67 - 4.35 (m, 1H), 4.12 - 3.95 (m, 1H), 3.60 (s, 3H), 3.14 - 2.82 (m, 2H), 1.44 (s, 9H).
[0316] (e) 5-( tert -butyl) 6-methyl ( S )-2-iodo-3-((2-trimethylsilyl)ethoxy) methyl)- 3,4,6,7-tetrahydro-5 H -Imidazo[4,5-c]pyridine-5,6-dicarboxylate
[0317] DIPEA (35.1 mL, 0.19 mol) was added at 0 °C to a stirred solution of 5-(tert-butyl)6-methyl(S)-2-iodo-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (40 g, 0.098 mol) in DMF (150 mL). The reaction mixture was stirred for 10 minutes, and then 2-(trimethylsilyl)-ethoxymethyl chloride (19.1 mL, 0.10 mol) was added dropwise at 0 °C. The resulting reaction mixture was stirred at room temperature for 3 hours. After 4 hours, cooling water was added, and the reaction mixture was extracted with EtOAc (2 x 200 mL). The organic layer was dried over anhydrous sodium sulfate, concentrated, and purified by flash column chromatography eluted with 20-35% EtOAc:hexane to provide the title product as a pale yellow viscous liquid (27 g). C 19 H 32 Regarding IN3O5Si ( m / z ): [M+H] + Calculated value 538.12 Measured value 538.42. 1 ¹H NMR (400 MHz, DMSO- d 6) δ 5.33 - 5.04 (m, 3H), 4.79 - 4.56 (m, 1H), 4.54 - 4.14 (m, 1H), 3.60 (s, 3H), 3.47 (t, J = 7.8 Hz, 2H), 3.31 - 3.16 (m, 1H), 2.97 (t, J = 18.9 Hz, 1H), 1.44 (s, 9H), 0.92 - 0.74 (m, 2H), -0.03 (s, 9H).
[0318] Preparation Example 11: (6S)-5-(tert-butoxycarbonyl)-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid
[0319]
[0320] (a) 5-( tert -butyl) 6-methyl (6 S )-2-(6-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-1-(tetrahydro-2 H-Evacuation-2-day)-1 H -indazole-3-yl)-3-((2-(trimethylsilyl) ethoxy) methyl)-3,4,6,7-tetrahydro-5 H -Imidazo[4,5-c]pyridine-5,6-dicarboxylate
[0321] 6-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-1-(tetrahydro-2H-pyran-2-yl)-3-(trimethylstanyl)-1H-indazole (20 g, 34.82 mmol) was added to a solution of 5-(tert-butyl)6-methyl(S)-2-iodo-3-((2-trimethylsilyl)ethoxy)methyl)-3,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5,6-dicarboxylate (17.0 g, 31.65 mmol) in toluene (500 mL). The above reaction mixture was purged with argon for 15 minutes, Pd(PPh3)4 (3.6 g, 3.16 mmol) and copper iodide (1.20 g, 6.33 mmol) were added, and the reaction mixture was stirred at 120°C for 16 hours. The reaction mixture was filtered through Celite, the filtrate was concentrated under reduced pressure, and purified by silica gel column chromatography (Redisep 80 g column, eluted with DCM for 10 minutes followed by eluted with 15-20% EtOAc in hexane) to provide the title intermediate as a yellow solid (15.10 g, 58% yield). C 46 H 58 For FN5O7Si ( m / z ): [M+H] + Calculated value 840.41, Measured value 840.54. 1 1H NMR (400 MHz, Chloroform- d ) δ 8.43 (s, 1H), 7.54 - 7.33 (m, 6H), 7.20 (s, 1H), 7.05 (d, J = 11.4 Hz, 1H), 6.95 (d, J= 8.5 Hz, 1H), 6.09 - 5.69 (m, 3H), 5.59 - 5.36 (m, 1H), 5.20 (s, 2H), 4.97 - 4.80 (m, 1H), 4.12 - 3.90 (m, 1H), 3.68 (s, 3H), 3.57 - 3.47 (m, 2H), 3.40 (d, 1H), 3.21 - 3.05 (m, 1H), 2.74 - 2.34 (m, 4H), 2.25 - 2.07 (m, 2H), 1.94 - 1.65 (m, 4H), 1.54 (s, 9H), 1.12 - 0.99 (m, 3H), 0.91 - 0.75 (m, 2H), -0.12 (s, 9H).
[0322] (b) 6-benzyl 5-( tert -butyl) (6 S )-2-(6-(4-(benzyloxy)-2-ethyl-5-fluorophenyl)-1-(tetrahydro-2 H -Evacuation-2-day)-1 H -indazole-3-yl)-3-((2-(trimethylsilyl) ethoxy) methyl)-3,4,6,7-tetrahydro-5 H -Imidazo[4,5-c]pyridine-5,6-dicarboxylate
[0323] The product of the previous step (15.0 g, 17.85 mmol) was added to toluene (400 mL), benzyl alcohol (46.3 mL), and Ti(OEt)4 (7.15 mL, 35.70 mmol) in a round-bottom flask, and the reaction mixture was vigorously refluxed (140 °C) for 48 hours, diluted with water, and extracted with DCM. The suspension was filtered, the filtrate was dried with Na2SO4, concentrated under reduced pressure, and purified by silica gel column chromatography (Redisep 80 g column, 0-5% EtOAc in hexane) for 20 minutes to remove excess benzyl alcohol, followed by elution with 10-15% EtOAc in hexane to provide the title intermediate, which matches the structure. 1 H NMR. C 52 H 62 (m / z) for FN5O7Si: [M+H] + Calculated value 916.44 Actual value 916.86.
[0324] (c) (6S)-5-(tert-butoxycarbonyl)-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid
[0325] Pd(OH)2 (5.0 g) was added to a stirred solution of the product from the previous step (21.0 g, 22.92 mmol) in 1:1 IPA:THF (400 mL). The reaction mixture was stirred at room temperature for 16 hours under a hydrogen balloon, filtered through Celite, concentrated under reduced pressure, and purified by silica gel column chromatography (Redisep 80 g column, eluted with 25-40% EtOAc in hexane) to yield the title compound (6.1 g, 8.29 mmol) as a grayish-white solid. C 38 H 50 (m / z) for FN5O7Si: [M+H] + Calculated value 736.35, measured value 736.5. Consistent with the structure 1 H NMR. C 38 H 50 (m / z) for FN5O7Si: [M+H] + Calculated value 736.35 Actual value 736.5. 1H NMR (400 MHz, DMSO-d6) δ 12.94 (s, 1H), 9.86 (s, 1H), 8.34 (t, J = 7.6 Hz, 1H), 7.66 (s, 1H), 7.20 (d, J = 8.7 Hz, 1H), 7.03 (d, J = 11.8) Hz, 1H), 6.93 (d, J = 9.1 Hz, 1H), 6.11 - 5.77 (m, 3H), 5.33 - 5.06 (m, 1H), 4.87 - 4.56 (m, 1H), 4.52 - 4.14 (m, 1H), 3.97 - 3.69 (m, 2H), 3.53 - 3.40 (m, 2H), 3.23 - 3.11 (m, 1H), 3.11 - 2.93 (m, 1H), 2.47 - 2.44 (m, 2H), 2.13 - 1.96 (m, 2H), 1.68 (d, J = 70.9 Hz, 4H), 1.48 (s, 9H), 1.02 (t, J = 7.5 Hz, 3H), 0.86 - 0.68 (m, 2H), -0.17 (s, 9H).
[0326] Preparation Example 12: (S)-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazole-3-yl)-4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine-6-carboxylic acid
[0327]
[0328] 5:1 Dioxane:Water (60 mL) (6 S )-5-( tert -butoxycarbonyl)-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1-(tetrahydro-2 H -Evacuation-2-day)-1 H -Indazole-3-yl)-3-((2-(trimethylsilyl)ethoxy)-methyl)-4,5,6,7-tetrahydro-3 H-Concentrated HCl (20 mL) was added dropwise at 0°C to a stirred solution of imidazo[4,5-c]pyridine-6-carboxylic acid (5.7 g, 7.75 mmol). The reaction mixture was heated at 90°C for 16 hours, stirred, and distilled under vacuum to yield a crude residue, which was sequentially softened with cooled diethyl ether and acetonitrile to yield the HCl salt of the title compound as a light brown solid (3.6 g, 95% yield). C 22 H 20 Regarding FN5O3 ( m / z ): [M+H] + Calculated value 422.16, Measured value 422.24. 1 ¹H NMR (400 MHz, D₂O / DMSO- d 6) δ 8.22 (d, J = 8.4 Hz, 1H), 7.49 (s, 1H), 7.19 (d, J = 8.1 Hz, 1 H), 6.99 (d, J = 11.9 Hz, 1 H), 6.91 (d, J = 9.0 Hz, 1H), 4.56 - 4.51 (m, 1H), 4.36 (d, J = 15.5 Hz, 1H), 4.30 (d, J = 15.5 Hz, 1H), 3.35 - 3.25 (m, 1H), 3.15 - 3.05 (m, 1H), 2.4 - 2.55 (m, 2H), 0.97 (t, J = 7.5 Hz, 3H).
[0329] Preparation Example 13: ( S )-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H -Imidazo[4,5-c]pyridine-6-carboxylic acid
[0330]
[0331] In DMF (7 mL) ( S )-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazole-3-yl)-4,5,6,7-tetrahydro-3H Sodium cyanoborohydride (274 mg, 4.37 mmol) was added to a solution of imidazo[4,5-c]pyridine-6-carboxylic acid, HCl (400 mg, 0.874 mmol), acetone (0.192 mL, 2.62 mmol), and acetic acid (0.150 mL, 2.62 mmol), and the reaction mixture was stirred overnight at RT. Sodium borohydride (33 mg, 0.874 mmol) was added, the solution was concentrated, and purified by preparative HPLC to yield the TFA salt of the title compound (115 mg, 23% yield). C 25 H 26 Regarding FN5O3 ( m / z ): [M+H] + Calculated value 464.20 Actual value 464.5.
[0332] Example 11: ( S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H -Imidazo[4,5-c]pyridin-6-yl)methanone C-1
[0333]
[0334] In DMF (4 mL) ( S )-2-(6-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H -Imidazoo[4,5-c]pyridine-6-carboxylic acid, TFA (179 mg, 0.310 mmol), N,N HATU (177 mg, 0.465 mmol) was added to a stirred solution of dimethylazetidin-3-amine, 2 HCl (107 mg, 0.465 mmol), and DIPEA (0.162 mL, 0.930 mmol), and the reaction mixture was stirred overnight at room temperature. Hydrazine (5 eq) was added, the reaction mixture was concentrated, and purified by preparative HPLC to yield the TFA salt of the title compound (63 mg, 26% yield). C 30 H 36Regarding FN7O2 ( m / z ): [M+H] + Calculated value 546.29, measured value 546.7. 1 ¹H NMR (400 MHz, DMSO- d 6) δ 9.90 (s, 1H), 8.29 (dd, 1H), 7.34 (s, 1H), 7.07 (d, 1H), 7.01 (d, 1H), 6.89 (d, 1H), 4.35 - 4.18 (m, 1H), 4.11 - 3.94 (m, 1H), 3.94 - 3.73 (m, 3H), 3.70 - 3.57 (m, 2H), 3.06 - 2.94 (m, 2H), 2.87 - 2.66 (m, 2H), 2.48 - 2.40 (m, 2H), 2.13 - 2.00 (m, 6H), 1.07 (t, 3H), 1.03 - 0.93 (m, 6H).
[0335] Biological analysis
[0336] compound 1 The characteristics of silver were identified in the following biological analysis.
[0337] Analytical Method 1: Biochemical JAK Kinase Analysis
[0338] A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3, and Tyk2) was performed in standard kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01% Brij-35, 10 mM MgCl2, and 1 mM EGTA). Recombinant GST-tagged JAK enzymes and GFP-tagged STAT1 peptide substrates were obtained from Life Technologies.
[0339] The series of diluted compounds were pre-incubated with each of the four JAK enzymes and substrates in a white 384-well microplate (Corning) at ambient temperature for 1 hour. Then, ATP was added to initiate the kinase reaction with a total volume of 10 μL with 1% DMSO. The final enzyme concentrations for JAK1, 2, 3, and Tyk2 were 4.2 nM, 0.1 nM, 1 nM, and 0.25 nM, respectively; the corresponding Km ATP concentrations used were 25 μM, 3 μM, 1.6 μM, and 10 μM; and the substrate concentration was 200 nM for all four analyses. The kinase reaction was allowed to proceed at ambient temperature for 1 hour before adding 10 μL of the formulation of EDTA (10 mM final concentration) and Tb-anti-pSTAT1 (pTyr701) antibody (Life Technologies, 2 nM final concentration) in TR-FRET dilution buffer (Life Technologies). The plate was incubated at ambient temperature for 1 hour before reading on an EnVision reader (Perkin Elmer). The release rate signal (520 nm / 495 nm) was recorded and used to calculate the percentage of inhibition based on DMSO and the background control.
[0340] For dose-response analysis, inhibition percentage data are plotted against compound concentration, and IC50 50 The values were determined from a 4-parameter robust fit model equipped with Prism software (GraphPad Software). The results were pIC 50 (IC 50 Expressed as the negative logarithm of, and subsequently using the Cheng-Prusoff equation, pK i It was converted to (the negative logarithm of the Harry constant Ki).
[0341] Lower K in 4 JAK analyses i value or higher pK iTest compounds with values exhibit greater inhibition of JAK activity.
[0342] Method 2: Inhibition of IL-2-stimulated pSTAT5 in Tall-1 T cells
[0343] The efficacy of the test compound for inhibiting interleukin-2 (IL-2)-stimulated STAT5 phosphorylation was measured in Tall-1 human T cell lines (DSMZ) using AlphaLisa. Since IL-2 signals through JAK1 / 3, this assay provides a measurement of JAK1 / 3 cell efficacy.
[0344] Phosphorylated STAT5 was measured using the AlphaLISA SureFire Ultra pSTAT5 (Tyr694 / 699) kit (PerkinElmer). Human T cells derived from the Tall-1 cell line were cultured in RPMI (Life Technologies) supplemented with 15% heat-inactivated fetal bovine serum (FBS, Life Technologies), 2 mM Glutamax (Life Technologies), 25 mM HEPES (Life Technologies), and 1X Pen / Strep (Life Technologies) in a 37°C, 5% CO2 humidified incubator. The compounds were serially diluted in DMSO and acoustically dispensed into empty wells. Assay medium (phenol red-free DMEM supplemented with 10% FBS (ATCC) (Life Technologies)) was dispensed (4 μL / well), and the plates were shaken at 900 rpm for 10 minutes. Cells were seeded at 45,000 cells / well in assay medium (4 μL / well) and incubated for 1 hour at 37°C and 5% CO2, and IL-2 (R&D Systems; final concentration 300 ng / mL) was added to the preheated assay medium (4 μL) for 30 minutes. After cytokine stimulation, cells were lysed with 6 μL of 3x AlphaLisa lysis buffer (PerkinElmer) containing 1x PhosStop and Complete Purification (Roche). The lysate was shaken at 900 rpm for 10 minutes at room temperature (RT). Phosphorylated STAT5 was measured using the pSTAT5 AlphaLisa kit (PerkinElmer). The freshly prepared receptor bead mixture was dispensed onto the lysate (5 μL) under green-filtered <100 lux light. The plate was shaken at 900 rpm for 2 minutes, briefly spin-down, and incubated at RT in a dark place for 2 hours.Donor beads were dispensed (5 μL) under green-filtered <100 lux light. The plate was shaken at 900 rpm for 2 minutes, briefly spin-down, and incubated overnight at RT in the dark. Luminescence was measured with excitation at 689 nm and emission at 570 nm using an EnVision plate reader (PerkinElmer) under green-filtered <100 lux light.
[0345] To determine the inhibitory efficacy of the test compound responding to IL-2, the average release intensity of beads binding to pSTAT5 was measured in human T cell lines. From the analysis of the inhibition curve of signal intensity against compound concentration, the IC50 50 The value was determined. The data is pIC 50 Value (IC) 50 It was expressed as the negative decimal logarithm of (mean ± standard deviation).
[0346] In vitro analysis results
[0347]
[0348] Method 3: Murine (mouse) model of IL-13-induced pSTAT6 induction in lung tissue
[0349] IL-13 is an important cytokine that forms the basis of the pathophysiology of asthma (Kudlacz et al. Eur. J. Pharmacol , 2008 , 582 IL-13 binds to cell surface receptors that activate members of the Janus family kinases (JAK), then phosphorylates STAT6, and subsequently activates additional transcriptional pathways. In the described model, a dose of IL-13 was delivered locally to the mouse lungs to induce phosphorylation of STAT6 (pSTAT6), which was then measured as an endpoint.
[0350] Harlan adult balb / c mice were used for this analysis. On the day of the study, animals were lightly anesthetized with isoflurane, and the vehicle or test compound (1 mg / mL, total volume 50 μL over several breaths) was administered via oral aspiration. After administration, the animals were placed in a lateral recumbency, and complete recovery from anesthesia was monitored before returning them to their home cages. Four hours later, the animals were lightly anesthetized again, and the vehicle or IL-13 (total delivered dose 0.03 μg, total volume 50 μL) was challenged via oral aspiration; recovery from anesthesia was monitored, and then they were returned to their home cages. One hour after administration of the vehicle or IL-13, Perkin Elmer AlphaLISA® SureFire ® Ultra™ HV Whole blood and lungs were collected using the p-STAT6 (Tyr641) assay kit for the detection of pSTAT6 in lung homogenates and for the analysis of total drug concentrations in lungs and plasma. Blood samples were centrifuged at approximately 12,000 rpm for 4 minutes at 4°C (Eppendorf centrifuge, 5804R) to collect plasma. Lungs were rinsed with DPBS (Dulbecco's Phosphate-Buffered Saline), pad-dried, flash-frozen, weighed, and homogenized by diluting 1:3 in 0.1% formic acid in HPLC water. Plasma and lung levels of the test compound were determined by LC-MS analysis against an analytical standard composed of a standard curve in the test matrix. The lung-to-plasma ratio was determined as the ratio of lung concentration in ng / g to plasma concentration in ng / mL at 5 hours.
[0351] Activity in the above model was demonstrated by a reduction in the level of pSTAT6 present in the lungs at 5 hours in treated animals compared to control animals treated with a vehicle and challenged with IL-13. The difference between the control animals treated with a vehicle and challenged with IL-13 and the control animals treated with a vehicle and challenged with a vehicle was represented by inhibitory effects of 0% and 100%, respectively, in any given experiment. Compound 1 As recorded below, it was challenged with IL-13 and showed inhibition of STAT6 phosphorylation after 5 hours.
[0352]
[0353] The observation of significant concentrations of the compound in mouse lungs confirmed that the observed IL-13-induced pSTAT6 inhibition was a result of the activity of the test compound. At 5 hours, the lung-to-plasma ratio was compound 1 It showed that there was significantly more exposure in the lungs than in the plasma of this mouse.
[0354] Method 4: Inhibition of TSLP-induced TARC release in human peripheral blood mononuclear cells
[0355] Thymic stromal lymphopoietin (TSLP) and thymus and activation-regulated chemokines (TARCs) are overexpressed in the airways of asthma patients and are associated with disease severity. In the lungs, TSLP can be released by bronchial epithelial cells in response to allergens and viral infections. TSLP signals via the IL-7Rα / TSLPR heterodimer, which is found in a wide range of tissues and cell types, including epithelial cells, endothelial cells, neutrophils, macrophages, and mast cells. Binding of TSLP to its receptors activates JAK1 and JAK2, inducing structural changes that phosphorylate various transcription factors, including STAT3 and STAT5. In immune cells, this triggers a series of intracellular events resulting in cell proliferation, anti-apoptosis, dendritic cell migration, and the production of Th2 cytokines and chemokines. In peripheral blood mononuclear cells (PBMCs), TSLP has an inflammatory effect by activating myeloid dendritic cells, a process mediated by the chemoattractant TARC, to attract and stimulate T cells.
[0356] In this analysis, TSLP stimulation was shown to induce TARC release from PBMCs, and this response was attenuated in a dose-dependent manner upon treatment with the compound. The efficacy of the test compound for inhibiting TARC release was measured.
[0357] PBMC alicotes from 3 to 5 donors (previously separated from whole blood and frozen with alicote at -80°C) were thawed at 37°C and dropwise added to 40 mL of preheated, sterile-filtered, complete RPMI medium in a 50 mL Falcon tube. The cells were pelleted and placed in complete medium at a concentration of 2.24 x 10⁻⁶ 6Cells were resuspended at cells / mL. Cells were seeded at 85 μL (190,000 cells) per well in tissue culture-treated 96-well flat-bottom microplates. Cells were incubated at 37°C with 5% CO2 for 1 hour.
[0358] The compound was obtained using a 10 mM stock solution in DMSO. A 3.7-fold serial dilution was performed to produce nine concentrations of the test compound in DMSO at a final analytical test concentration of 300X. An intermediate dilution of 150-fold was performed in complete medium to produce the compound at a final analytical test concentration of 2X in 0.2% DMSO. After an incubation period of 1 hour, 95 μL of the 2X compound was added to each well of the PBMC for a final analytical concentration range of 33.33 μM to 0.95 μM. 95 μL of 0.2% DMSO in complete medium was added to the untreated control wells. Prior to cell stimulation, the cells were pre-treated with the compound for 1 hour at 37°C with 5% CO2.
[0359] Recombinant human TSLP protein was reconstituted to 10 μg / mL in sterile DPBS containing 0.1% BSA and stored in Alicort at -20°C. Immediately before use, Alicort was thawed and prepared to a final assay concentration of 20X in complete medium. For a final assay concentration of 10 ng / mL, 10 μL of 20X TSLP was added to each well of PBMC. 10 μL of complete medium was added to unstimulated control wells. Cells were stimulated with 5% CO2 at 37°C for 48 hours in the presence of the compound.
[0360] After stimulation, the cell culture supernatant was harvested, and TARC levels were detected by enzyme-linked immunosorbent assay (ELISA) using the human CCL17 / TARC Quantikine ELISA kit (R&D Systems #DDN00) according to the manufacturer's instructions.
[0361] For dose-response analysis, log[test compound (M)] was plotted against the percentage of response values for each donor, and IC 50 The values were determined using nonlinear regression analysis with GraphPad Prism software employing a 4-parameter sigmoidal dose-response algorithm with variable gradients. The data were the pICs of individual donors. 50 Average pIC calculated from the values 50 (Negative decimal logarithm IC 50 The values were expressed as ) and rounded to the first decimal place. The inhibitory efficacy values of the original compounds and their des-fluoro variant analogs are summarized in Table 7 below.
[0362]
[0363] Analysis Method 5: Lung S9 Metabolism
[0364] compound 1 and C-1The in vitro metabolic stability of was evaluated in human lung S9 fractions (1 μM compound, 1 mg / mL S9 protein). Samples at times 0, 15, 30, and 60 min were analyzed for the parent compound by high-resolution LC-MS / MS. Human lung S9 fractions (Lot 1410245) were purchased from XenoTech LLC (Lenexa, KS). NADPH (Sigma Aldrich, N1630) and 3-phosphoadenosine 5-phosphosulfate (PAPS) (Sigma Aldrich, A1651) were purchased from Sigma Aldrich (St. Louis, MO). Acetonitrile and water were obtained from VWR (Radnor, PA) and were HPLC grade or higher. Raloxifene and formic acid were purchased from Sigma Aldrich (St. Louis, MO). S9 incubation was performed in a 37°C water bath in a 96-well polypropylene plate. The waste S9 solution consisted of 100 mM potassium phosphate (BD Biosciences, Woburn, MA) buffered to pH 7.4 supplemented with 1 mM NADPH (Sigma-Aldrich, St. Louis, MO) and 3 mM magnesium chloride (Sigma Aldrich, M1028), and 100 μM PAPS (Sigma-Aldrich, St. Louis, MO) cofactor was present, with a final incubation protein concentration of 1 mg / mL. 10 mM DMSO stocks of raloxifene (n=1) and compound (n=1) were diluted in buffer and added to the incubation to produce a substrate concentration of 1 μM (0.001% DMSO v / v). The incubation volume was 400 μL, and at time points of 0, 15, 30, and 60 minutes, 70 μL of alicote was removed and the sample was diluted with 140 μL of acetonitrile (0% formic acid) for measurement. All samples were centrifuged at 2250 g for 10 minutes at 5°C. The supernatant (50 μL) from the centrifuged samples was taken and diluted in 100 μL of HPLC water containing an internal standard.Samples were run on a Dionex Ultimate 3000 automatic sampler and analyzed using a Thermo Q-Exactive high-resolution mass spectrometer (Thermo, Waltham, MA) in Full Scan mode with an Atlantis T3 column 3μM - 2.1 x 50 mm (Waters Inc., 186003717). Mobile phase A consisted of water + 0.2% formic acid, and mobile phase B consisted of acetonitrile + 0.2% formic acid. Peak integration was performed using Gubbs GMSU software (Gubbs Inc., Alpharetta, GA). For each sample, the peak area ratio was calculated by dividing the analyte peak area by the internal standard peak area. For each incubation, the analyte peak area ratio at each t0 was set to 100%, and the peak area ratio of the 60-minute sample was converted to the remainder percentage relative to the corresponding t0. The determination of sulfate metabolite formation was qualitatively performed based on historical internal data by observing the early-eluting peaks of the parent ion channels corresponding to the O-sulfate metabolites of each parent compound. The results of the above analysis are summarized in Table 8 below (n=2 replicates).
[0365]
[0366] Corresponding fluoro analogue (compound) C-1 When compared to ), compound 1 It caused significantly less sulfation metabolism.
[0367] Analytical Method 6: Pharmacokinetics in Mouse Plasma and Lungs
[0368] Plasma and lung concentrations of the test compound and their ratios were determined in the following manner. BALB / c mice from Charles River Laboratories were used for this analysis. The test compound was individually formulated in 20% propylene glycol in pH 4 citrate buffer at a concentration of 0.2 mg / mL, and 50 μL of the administration solution was introduced into the mice's airways by oral suction. At various time points after administration (typically 0.167, 2, 6, and 24 hours), blood samples were obtained via cardiac puncture, and intact lungs were resected from the mice. Plasma was collected by centrifuging the blood samples at approximately 12,000 rpm for 4 minutes at 4°C (Eppendorf centrifuge, 5804R). The lungs were pad-dried, weighed, and homogenized by diluting them 1:3 in sterile water. Plasma and lung concentrations of the test compound were determined by LC-MS analysis against an analytical standard constructed from a standard curve of the test matrix. The lung-to-plasma ratio was determined as the ratio of the lung AUC at μg hr / g to the plasma AUC at μg hr / g, where AUC is typically defined as the area under the curve of test compound concentration versus time.
[0369]
[0370] Method 7: Inhibition of IFNγ and IL-27-induced chemokines CXCL9 and CXCL10 in human 3D airway cultures
[0371] EpiAirway tissue cultures were obtained from Mattek (AIR-100). The cultures were derived from asthma donors. In cell culture inserts, human-derived tracheal / bronchial epithelial cells were proliferated and differentiated on porous membrane supports to allow an air-liquid interface with warmed culture medium below the cells and a gaseous test atmosphere above. Tissues were cultured in maintenance medium (Mattek, AIR-100-MM) in a 37°C, 5% CO2 humidified incubator. Four donors were tested. On Day 0, tissue cultures were treated at the liquid interface with test compounds at concentrations of 10 μM, 1 μM, and / or 0.1 μM. Compound 1 It was diluted in dimethyl sulfoxide (DMSO, Sigma) to a final concentration of 0.1%. 0.1% DMSO was used as a vehicle control. Compound 1 The culture was incubated with the compound at 37°C and 5% CO2 for 1 hour, and pre-warmed medium containing IFNγ (R&D Systems) or IL-27 (R&D Systems) at a final concentration of 100 ng / ml was added. The tissue culture was maintained for 8 days. The medium was compound 1 and the medium was replaced every 2 days with fresh medium containing IFNγ or IL-27. On day 8, tissue cultures and supernatants were collected for analysis. Supernatant samples were analyzed for CXCL10 (IP-10) and CXCL9 (MIG) using the Luminex assay (EMD Millipore). Data were expressed as % inhibition + / - standard deviation (±STDV). The percentage of inhibition was determined by the inhibitory efficacy of the compounds on IFNγ or IL-27-induced CXCL10 or CXCL9 secretion compared to vehicle-treated cells. Data are the average from four donors. Compound 1The compound can inhibit IFNγ-induced CXCL10 secretion by 100% ±1.0 (at 10 μM), 76% ±13 (at 1 μM), and 18% ±22 (at 0.1 μM) compared to the vehicle control. 1 The compound can inhibit IFNγ-induced CXCL9 secretion by 100% ±0.1 (at 10 μM), 93% ±6.9 (at 1 μM), and 16% ±41 (at 0.1 μM) compared to the vehicle. 1 The compound can inhibit IL-27-induced CXCL10 secretion by 100% ±0.0 (at 10 μM), 98% ±1.0 (at 1 μM), and 25% ±26 (at 0.1 μM) compared to the vehicle control. 1 It can inhibit IL-27-induced CXCL9 secretion by 100% ±0.0 (at 10μM), 97% ±2.0 (at 1μM), and 52% ±18 (at 0.1μM) when compared to the vehicle control.
[0372] Method 8: Cellular JAK Efficacy Analysis: Inhibition of IFNγ-induced pSTAT1
[0373] Compounds for the inhibition of interferon gamma (IFNγ)-stimulated STAT1 phosphorylation 1 The efficacy was measured in CD14-positive (CD14+) monocytes derived from human whole blood (Stanford Blood Center) using a flow cytometer. Since IFNγ signals via JAK, this analysis provides a measurement of JAK cell efficacy.
[0374] Monocytes were identified using a fluorescein isothiocyanate (FITC) conjugated anti-CD14 antibody (Clone RM052, Beckman Coulter), and an Alexa Fluor 647 conjugated anti-pSTAT1 antibody (pY701, Clone 4a, BD Biosciences) was used to detect STAT1 phosphorylation.
[0375] Human peripheral blood mononuclear cells (PBMCs) were isolated from human whole blood from healthy donors using a Ficoll gradient. Cells were cultured in RPMI (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Life Technologies), 2 mM Glutamax (Life Technologies), 25 mM HEPES (Life Technologies), and 1X Pen / Strep (Life Technologies) in a 37°C, 5% CO2 humidified incubator. Cells were seeded at 250,000 cells / well in 200 μL of medium, cultured for 2 hours, and resuspended in 50 μL of assay medium (RPMI supplemented with 0.1% bovine serum albumin (Sigma), 2 mM Glutamax, 25 mM HEPES, and 1X Penstrep) containing various concentrations of the test compounds. The compounds were serially diluted in DMSO and then further diluted 1,000-fold in the medium to a final DMSO concentration of 0.1%. The test compound dilution was incubated with cells at 37°C and 5% CO2 for 1 hour, and then IFNγ (R&D Systems) was added to pre-warmed medium (50 μL) at a final concentration of 0.6 ng / mL for 30 minutes. After cytokine stimulation, cells were fixed with pre-warmed fixation solution (100 μL) (BD Biosciences) for 10 minutes at 37°C and 5% CO2, washed twice with FACS buffer (1 mL) (1% BSA in PBS), resuspended in 1:10 anti-CD14 FITC:FACS buffer (100 μL), and incubated at 4°C for 15 minutes. Cells were washed once and then resuspended in ice-cold Perm buffer III (BD Biosciences) (100 μL) at 4°C for 30 minutes.Cells were washed twice with FACS buffer, then resuspended in 1:10 anti-pSTAT1 Alexa Fluor 647:FACS buffer (100 μL) at room temperature in the dark for 30 minutes, washed twice with FACS buffer, and analyzed using a MACSQuant flow cytometer (Miltenyi).
[0376] To determine the inhibitory efficacy of the test compound, the median fluorescent intensity (MFI) of pSTAT1 was measured in CD14+ monocytes. IC 50 The values were determined from the analysis of the inhibition curve of MFI versus compound concentration. The data were pIC 50 (negative ten logarithm IC 50 It was expressed as a value. Compound 1 pIC in this analysis 50 The value was approximately 7.5.
[0377] Method 9: Cellular JAK Efficacy Analysis: Inhibition of GM-CSF-Induced pSTAT5
[0378] Compounds for the inhibition of granulocyte-macrophage colony-stimulating factor (GM-CSF)-stimulated STAT5 phosphorylation 1 The efficacy was measured in CD14-positive (CD14+) monocytes derived from human whole blood (Stanford Blood Center) using a flow cytometer. Since GM-CSF signals via JAK, this analysis provides a measurement of JAK cell efficacy.
[0379] Monocytes were identified using a fluorescein isothiocyanate (FITC) conjugated anti-CD14 antibody (Clone RM052, Beckman Coulter), and an Alexa Fluor 647 conjugated anti-pSTAT5 antibody (pY694, BD Biosciences) was used to detect STAT5 phosphorylation.
[0380] Human peripheral blood mononuclear cells (PBMCs) were isolated from human whole blood from healthy donors using a Ficoll gradient. Cells were cultured in RPMI (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Life Technologies), 2 mM Glutamax (Life Technologies), 25 mM HEPES (Life Technologies), and 1X Pen / Strep (Life Technologies) in a 37 °C, 5% CO2 humidified incubator. Cells were seeded at 250,000 cells / well in medium (200 μL), cultured for 2 hours, and resuspended in assay medium (50 μL) containing various concentrations of test compounds (RPMI supplemented with 0.1% bovine serum albumin (Sigma), 2 mM Glutamax, 25 mM HEPES, and 1X Penstrep). The compounds were serially diluted in DMSO and then further diluted 1,000-fold in the medium to a final DMSO concentration of 0.1%. The test compound dilution was incubated with cells at 37°C and 5% CO2 for 1 hour, and then GM-CSF (R&D Systems) was added to pre-warmed medium (50 μL) at a final concentration of 0.3 ng / mL for 15 minutes. After cytokine stimulation, cells were fixed with pre-warmed fixation solution (100 μL) (BD Biosciences) for 10 minutes at 37°C and 5% CO2, washed twice with FACS buffer (1 mL) (1% BSA in PBS), resuspended in 1:10 anti-CD14 FITC:FACS buffer (100 μL), and incubated at 4°C for 15 minutes. Cells were washed once and then resuspended in ice-cold Perm buffer III (BD Biosciences) (100 μL) at 4°C for 30 minutes.Cells were washed twice with FACS buffer, then resuspended in 1:10 anti-pSTAT1 Alexa Fluor 647:FACS buffer (100 μL) at room temperature in the dark for 30 minutes, washed twice with FACS buffer, and analyzed using a MACSQuant flow cytometer (Miltenyi).
[0381] To determine the inhibitory efficacy of the test compound, the median fluorescent intensity (MFI) of pSTAT5 was measured in CD14+ monocytes. IC 50 The values were determined from the analysis of the inhibition curve of MFI versus compound concentration. The data were pIC 50 (negative ten logarithm IC 50 It was expressed as a value. Compound 1 pIC in this analysis 50 The value was approximately 6.9.
[0382] Method 10: Cellular JAK Efficacy Analysis: Inhibition of IL-12-Induced pSTAT4
[0383] Compounds for the inhibition of interleukin-12 (IL-12)-stimulated STAT4 phosphorylation 1 The efficacy was measured in CD3-positive (CD3+) T cells derived from human whole blood (Stanford Blood Center) using a flow cytometer. Since IL-12 signals via JAK, this analysis provides a measurement of JAK cell efficacy.
[0384] CD3+ T cells were identified using a phycoerythrin (PE) conjugated anti-CD3 antibody (clone UCHT1, BD Biosciences), and an Alexa Fluor 647 conjugated anti-pSTAT4 antibody (clone 38 / p-Stat4, BD Biosciences) was used to detect STAT4 phosphorylation.
[0385] Human peripheral blood mononuclear cells (PBMCs) were isolated from human whole blood from healthy donors using a Ficoll gradient. Cells were cultured in RPMI (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Life Technologies), 2 mM Glutamax (Life Technologies), 25 mM HEPES (Life Technologies), 1X Pen / Strep (Life Technologies), plate-conjugated purified anti-CD3 antibody (5 μg / ml, clone UCHT1, BD Biosciences), and soluble anti-CD28 antibody (1 μg / ml, clone CD28.2, BD Biosciences) in a 37°C, 5% CO2 humidified incubator. Cells were harvested, washed with medium, and resuspended in medium containing Interleukin-2 (IL-2, 10 ng / ml, R&D Systems). Cells were cultured for 3 days at 37°C, 5% CO2. Cells were cultured in a humidified incubator. Cells were harvested, washed with RPMI, seeded at 250,000 cells / well in medium (200 μL), cultured for 2 hours, and resuspended in assay medium (50 μL) containing various concentrations of test compounds (RPMI supplemented with 0.1% bovine serum albumin (Sigma), 2 mM Glutamax, 25 mM HEPES, and 1X Penstrep). The compounds were serially diluted in DMSO and then further diluted 1000-fold in the medium to a final DMSO concentration of 0.1%. The test compound dilutions were incubated with the cells at 37 °C and 5% CO2 for 1 hour, and then IL-12 (R&D Systems) was added in pre-warmed medium (50 μL) at a final concentration of 10 ng / mL for 30 minutes. After cytokine stimulation, cells were fixed in pre-warmed fixation solution (100 μL) (BD Biosciences) for 10 minutes at 37°C and 5% CO2, washed twice with FACS buffer (1 mL) (1% BSA in PBS), and resuspended in ice-cold Perm buffer III (1000 μL) (BD Biosciences) at 4°C for 30 minutes. Cells were washed twice with FACS buffer and then resuspended in FACS buffer (100 μL) containing anti-CD3 PE (1:50 dilution) and anti-pSTAT4 Alexa Fluor 647 (1:10 dilution) for 45 minutes in the dark at room temperature. After incubation, cells were washed twice in FACS buffer before analysis using a MACSQuant flow cytometer (Miltenyi). To determine the inhibitory efficacy of the test compound, the median fluorescence intensity (MFI) of pSTAT4 was measured in CD3+ T cells. IC 50 The values were determined from the analysis of the inhibition curve of MFI versus compound concentration. The data were pIC 50 (negative ten logarithm IC 50 It was expressed as a value. Compound 1pIC in this analysis 50 The value was approximately 6.0.
[0386] Analysis Method 11: Inhibition of IFNγ secretion in mixed lymphocyte response analysis
[0387] The mixed lymphocyte response assay is an in-vitro assay that mimics transplant rejection. T cells derived from one donor are cultured with allogeneic dendritic cells derived from another donor. This reaction induces cellular immune responses, such as IFNγ secretion.
[0388] CD14+ monocytes were isolated from human whole blood (Stanford blood center) from donor A using a ficoll gradient and magnetic separation (CD14 micro beads, Miltenyi). Monocytes were differentiated into dendritic cells by culturing the cells for 6 days in RPMI (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Life Technologies), 2 mM Glutamax (Life Technologies), 1X Pen / Strep (Life Technologies), interleukin-4 (IL-4, 50 ng / ml, R&D Systems), and granulocyte-macrophage colony-stimulating factor (GM-CSF, 50 ng / ml, R&D Systems) in a 37°C, 5% CO2 humidified incubator. Dendritic cells were harvested, washed with medium, and activated by incubating them in medium containing Escherichia coli lipopolysaccharide (LPS, 100 ng / ml, Sigma) in a 37°C, 5% CO2 humidified incubator for 24 hours. Cells were harvested, washed with medium, resuspended in medium at 400,000 cells / ml, and plated at 10,000 cells / well / 25 μl. CD4+ T cells were freshly isolated from human whole blood (Stanford blood center) from donor B using a Ficoll gradient and magnetic separation (CD4+ T cell separation kit, Miltenyi). T cells were resuspended at 4,000,000 cells / ml in RPMI (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Life Technologies), 2 mM Glutamax (Life Technologies), 25 mM HEPES (Life Technologies), and 1X Pen / Strep (Life Technologies). CD4+ T cells were mixed with dendritic cells at a rate of 100,000 cells / well / 25 μl. Cells were treated with test compounds (50 μl at 20 μM, 2 μM, and / or 0.2 μM) to a final concentration of 10 μM, 1 μM, and / or 0.It was adjusted to 1 μM. Compound. 1 It was diluted in dimethyl sulfoxide (DMSO, Sigma) to a final concentration of 0.1%. 0.1% DMSO was used as a vehicle control. Cells were heated for 5 days at 37°C under 5% CO2. They were maintained in a humidified incubator. On day 5, the supernatant was collected and measured for interferon gamma (INFγ) using enzyme-linked immunosorbent assay (ELISA). The percentage of inhibition was determined by the inhibitory efficacy of the compound on IFNγ secretion compared to vehicle-treated cells. The data are the average from four donors. Compound 1 Compared to the vehicle control, it was able to inhibit IFNγ secretion by 99% ±0.4 (at 10μM), 76% ±10 (at μM), and 43% ±12 (at 0.1μM).
[0389] Method 12: Inhibition of spontaneous periostin and IL-6 secretion in human 3D airway cultures derived from asthma donors
[0390] EpiAirway tissue cultures were obtained from Mattek (AIR-100). Cells were derived from asthma donors that spontaneously secrete periostin, a matricellular protein associated with Th2-mediated asthma (eosinophilic), and interleukin-6 (IL-6), an inflammatory cytokine that plays a role in both Th2 and non-Th2 related asthma. In cell culture inserts, human-derived tracheal / bronchial epithelial cells were proliferated and differentiated on porous membrane supports to allow for an air-liquid interface with warmed culture medium below the cells and a gaseous test atmosphere above. Tissues were cultured in maintenance medium (Mattek, AIR-100-MM) in a 37°C, 5% CO2 humidified incubator. Four donors were tested. On Day 0, tissue cultures were treated at the liquid interface with test compounds at concentrations of 10 μM, 1 μM, and / or 0.1 μM. Compound 1It was diluted in dimethyl sulfoxide (DMSO, Sigma) to a final concentration of 0.1%. 0.1% DMSO was used as a vehicle control. Tissue cultures were maintained for 8 days. The medium was a compound 1 The medium was replaced every 2 days with fresh medium containing [substance]. On day 8, the supernatant was collected for analysis. Supernatant samples were analyzed for periostin and interleukin-6 (IL-6) using the Luminex assay (EMD Millipore). Data were expressed as % inhibition + / - standard deviation (±STDV). The percentage of inhibition was determined by the inhibitory efficacy of the compounds on spontaneous periostin and IL-6 secretion compared to vehicle-treated cells. Data are the average of 3 or 4 donors. Compound 1 The compound was able to inhibit spontaneous periostin secretion by 62% ±25 (at 10μM) and 40% ±28 (at 1μM) compared to the vehicle control group. 1 It was able to inhibit spontaneous IL-6 secretion by 91% ±9.0 (at 10μM), 70% ±33 (at 1μM), and 10% ±40 (at 0.1μM) compared to the vehicle.
[0391] Crystal structure
[0392] Compound bound to human JAK1 at a resolution of 2.28 Å C-1's A co-crystal structure was obtained. The ligand was observed to bind to the ATP binding site. Seven specific hydrogen bond interactions were identified based on a distance of 3.5 Å or less between the donor and acceptor atoms. In particular, C-1Hydrogen bonding interactions were identified between the carbonyl of the exocyclic amide of the compound and the Arg879 side chain of JAK1. In initial modeling studies, these interactions were proposed as a mechanism providing selectivity to JAK1 over other tyrosine kinases, as other closely related kinases (e.g., TRKA, VEGFR, ABL1) do not possess arginine residues at equivalent positions. The observed results regarding hydrogen bonding interactions in the crystal structure and improved kinome selectivity compared to a series without exocyclic amides validate this design hypothesis.
[0393] Although the present disclosure has been described with reference to specific aspects or embodiments thereof, it will be understood by those skilled in the art that various modifications may be made or equivalents substituted without departing from the true spirit and scope of the present disclosure. Furthermore, to the extent permitted by applicable patent laws and regulations, all publications, patents, and patent applications cited herein are incorporated by reference in their entirety, to the same extent as if each document were individually incorporated herein by reference.
Claims
Claim 1 The following chemical formula 1 As a crystal hydrate of the compound: The crystal hydrate is characterized in that the powder X-ray diffraction pattern includes diffraction peaks at 2θ values of 5.68±0.20, 10.43±0.20, 10.94±0.20, and 13.08±0.
20. Claim 2 A crystal hydrate according to claim 1, wherein the powder X-ray diffraction pattern has one additional diffraction peak at a 2θ value of 8.49±0.
20. Claim 3 A crystal hydrate according to claim 2, wherein the powder X-ray diffraction pattern has two or more additional diffraction peaks at 2θ values selected from 11.55±0.20, 12.20±0.20, 17.06±0.20, and 26.29±0.
20. Claim 4 A crystal hydrate according to claim 2, wherein the powder X-ray diffraction pattern has additional diffraction peaks at 2θ values of 11.55±0.20, 12.20±0.20, 17.06±0.20, and 26.29±0.
20. Claim 5 A crystal hydrate according to claim 1, wherein the crystal hydrate is characterized by a powder X-ray diffraction pattern in which the peak position coincides with the peak position of the pattern shown in FIG. 1 below: [Fig. 1] . Claim 6 A crystal hydrate according to claim 1, characterized in that a differential scanning calorimetry trace recorded at a heating rate of 10 °C / min shows a maximum endothermic heat flow at a temperature of 212.4 ± 3 °C. Claim 7 A crystal hydrate according to claim 1, wherein the crystal hydrate is characterized in that the differential scanning calorimetry trace matches that shown in FIG. 2 below: [Fig. 2] . Claim 8 The crystal hydrate of claim 1, wherein the crystal hydrate is a monohydrate. Claim 9 A pharmaceutical composition for treating inflammatory respiratory diseases in mammals, comprising a crystal hydrate of any one of claims 1 to 8 as an active ingredient. Claim 10 A method for producing a crystal hydrate according to any one of claims 1 to 8, comprising the following steps: (a) ( S )-(3-(dimethylamino)azetidine-1-yl)(2-(6-(2-ethyl-4-hydroxyphenyl)-1 H -Indazole-3-yl)-5-isopropyl-4,5,6,7-tetrahydro-3 H - A step of providing a solution by dissolving imidazo[4,5-c]pyridine-6-yl)methanone in an alcohol solvent at 55°C ± 10°C; (b) a step of cooling the solution obtained in step (a) to 10°C ± 10°C to produce a suspension; (c) a step of separating a solid from the suspension of step (b) under inert gas conditions; and (d) a step of drying the solid obtained in step (c) at 60°C ± 15°C. Claim 11 A method according to claim 10, wherein the alcohol solvent is methanol or ethanol. Claim 12 In claim 9, the inflammatory respiratory disease is asthma, chronic obstructive pulmonary disease, cystic fibrosis, pneumonia, idiopathic pulmonary fibrosis, acute lung injury, acute respiratory distress syndrome, bronchitis, emphysema, sarcoidosis, eosinophilic disease, helminth infection, pulmonary arterial hypertension, lymphangioleiomyomatosis, bronchiectasis, infiltrative lung disease, drug-induced pneumonia, fungal-induced pneumonia, allergic bronchopulmonary aspergillosis, hypersensitivity pneumonia, eosinophilic granulomatosis with polyangiitis, idiopathic acute eosinophilic pneumonia, idiopathic chronic eosinophilic pneumonia, hypereosinophilic syndrome, Loeffler syndrome (L A pharmaceutical composition selected from the group consisting of Fffler syndrome), bronchiolitis obliterans organizing pneumonia, lung graft-versus-host disease, and immune-check-inhibitor-induced pneumonia. Claim 13 A pharmaceutical composition according to claim 9, wherein the inflammatory respiratory disease is asthma. Claim 14 A pharmaceutical composition according to claim 13, wherein the asthma is moderate to severe asthma. Claim 15 A pharmaceutical composition according to claim 9, wherein the crystal hydrate is administered by inhalation within the pharmaceutical composition. Claim 16 A pharmaceutical composition for preventing or delaying lung transplant rejection in mammals, comprising a crystal hydrate of any one of claims 1 to 8 as an active ingredient. Claim 17 A pharmaceutical composition according to claim 16, wherein the lung transplant rejection reaction is selected from the group consisting of primary graft dysfunction, organizing pneumonia, acute rejection reaction, lymphocytic bronchiolitis, and chronic lung allograft dysfunction. Claim 18 A pharmaceutical composition according to claim 16, wherein the lung transplant rejection reaction is an acute lung transplant rejection reaction. Claim 19 A pharmaceutical composition according to claim 16, wherein the lung transplant rejection reaction is a chronic lung allograft dysfunction. Claim 20 A pharmaceutical composition according to claim 16, wherein the lung transplant rejection reaction is selected from the group consisting of bronchiolitis obliterans, limited chronic lung allograft dysfunction, and neutrophilic allograft dysfunction. Claim 21 A pharmaceutical composition according to claim 16, wherein the crystal hydrate is administered by inhalation within the pharmaceutical composition. Claim 22 delete Claim 23 delete Claim 24 delete Claim 25 delete Claim 26 delete Claim 27 delete Claim 28 delete Claim 29 delete Claim 30 delete Claim 31 delete Claim 32 delete Claim 33 delete Claim 34 delete Claim 35 delete Claim 36 delete Claim 37 delete Claim 38 delete Claim 39 delete Claim 40 delete Claim 41 delete Claim 42 delete Claim 43 delete Claim 44 delete
Citation Information
Patent Citations
4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2017077288A1
Fused imidazo-piperidine JAK inhibitors
WO2018165395A1
Crystalline forms of a JAK inhibitor compound
WO2018204236A1
Dimethyl amino azetidine amides as JAK inhibitors
WO2020051105A1
